UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, DC 20549

 

SCHEDULE 14A

 

PROXY STATEMENT PURSUANT TO SECTION 14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )

 

Filed by the Registrant

Filed by a Party other than the Registrant

 

Check the appropriate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
	Definitive Proxy Statement
	Definitive Additional Materials
	Soliciting Material under §240.14a-12

 

 

Amneal Pharmaceuticals, Inc.

 

(Name of Registrant as Specified in Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):
	No fee required.
	Fee paid previously with preliminary materials.
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

Notice of 2024

Annual Meeting of Stockholders
and Proxy Statement

 

You are cordially invited to attend the Amneal Pharmaceuticals, Inc. 2024 Annual Meeting of Stockholders. THURSDAY, MAY 2, 2024 9:00 a.m., Eastern Daylight Time Virtual Meeting at www.virtualshareholdermeeting.com/AMRX2024 Items to be Voted On 1.    Elect as directors the 11 nominees named in the accompanying proxy statement; 2.    Approve the compensation of our named executive officers on an advisory basis; 3.    Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal year 2024; and 4.    Transact such other business as may properly come before the annual meeting or any adjournment or postponement of the meeting.   Record Date You are eligible to vote if you were a stockholder of record at the close of business on March 11, 2024. A list of stockholders of record will be made available to stockholders during the meeting at www.virtualshareholdermeeting.com/AMRX2024 when you enter your 16-Digit Control Number.

Voting Your vote is important, and you are invited to attend the annual meeting. Whether or not you expect to attend the annual meeting, we encourage you to vote as soon as possible. To ensure your shares are voted, you may vote your shares in advance of the meeting over the internet, by telephone or, if you requested to receive printed proxy materials, by mailing a proxy or voting instruction card. Voting over the internet, by telephone or by mail will ensure your representation at the annual meeting regardless of whether you attend the meeting.   Virtual Annual Meeting We are once again hosting a virtual meeting this year. The live audio webcast will be available at www.virtualshareholdermeeting.com/AMRX2024.   This proxy statement and the related materials are first being distributed or made available to stockholders on or about March 22, 2024.   By Order of the Board of Directors, Jason B. Daly Senior Vice President, Chief Legal Officer & Corporate Secretary   Bridgewater, New Jersey March 22, 2024

 

Review your proxy statement and vote in advance of the meeting in one of three ways:
INTERNET	BY TELEPHONE	BY MAIL
Visit the website on your proxy card	Call the telephone number on your proxy card	Sign, date and return your proxy card in the enclosed envelope
Please refer to the enclosed proxy materials or the information forwarded by your bank, broker or other holder of record to see which voting methods are available to you. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on May 2, 2024: The notice of annual meeting, this proxy statement and our annual report on Form 10-K for the fiscal year ended December 31, 2023 are available at www.proxyvote.com.

 

To

Our Fellow Stockholders, Stakeholders and Colleagues,

 

AMNEAL PHARMACEUTICALS’ INC. AT-A-GLANCE

 

WHAT DO WE DO?

 

We founded Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) in 2002 to provide access to affordable medicines. Amneal is a global, vertically integrated, and diversified pharmaceuticals company. We provide over 7,700 high-quality jobs and help consumers obtain access to the medicines they need.

 

WHAT IS OUR STRATEGY?

 

We are focused on providing high-quality, affordable medicines to patients and creating value for all stakeholders. Our strategy is sharply focused, yet we believe provides the appropriate flexibility needed to navigate an unpredictable healthcare environment where cost pressures are acute. Key elements supporting our value creation strategy include:

 

•	Operating large-scale, in-house best-in-class manufacturing facilities globally;
•	Creating a carefully funded research and development platform to feed a large and diverse pipeline of over 160 pipeline programs to supplement our current portfolio of more than 270 marketed commercial products;
•	Executing on a strategy to steadily move up the value chain to more complex and difficult-to-manufacture products that offset the steady erosion of our base Generics business and that have higher barriers to entry and more defensible revenue streams, including:
	•	Our move into biosimilars and sterile injectables, which typically have more durable revenue streams with institutional customers;
	•	Our participation in the federal healthcare sector through AvKARE, which diversifies our channel mix;
	•	Our Specialty segment, which benefits from a truly differentiated platform in neurology and endocrinology that helps us serve large populations with unmet needs and leverage our existing commercial infrastructure; and
	•	Our accelerating entry into key international markets including Europe, Asia-Pacific and other opportunistic emerging markets helping us strengthen the value of our high-value portfolio products in new ways;
•	Maintaining collaborative relationships with regulators and sustaining an excellent track record within the industry, with no major observations at our sites to date;
•	Steadily broadening our scientific and industry expertise through management of and partnership with adjacent life-sciences areas;
•	Making strategic acquisitions in adjacent life sciences areas to enable continual and rapid pivoting and learning; and
•	Responding to an evolving global regulatory environment that requires increased corporate disclosure of climate and business risks by:
	•	Preparing the company for disclosing its global environmental footprint, which has involved the introduction of a new carbon accounting software for tracking scope 1 and scope 2 greenhouse gas emissions in all of our global manufacturing operations;
	•	Increasing governance around climate and business risk through oversight of our Board of Directors and its committees, a cross-functional internal taskforce, and rigorous data management processes and approvals; and
	•	Reporting on our corporate impact via our annual 2023 Environmental, Social and Governance (“ESG”) report. The report was tracked against the United Nations Sustainable Development Goals and the Sustainability Accounting Standards Board Biotechnology and Pharmaceuticals Standard.

 

Further information about our Corporate Responsibility programs are available at https://www.amneal.com/about/responsibility. Please note that this website and our ESG Reports are not part of our public disclosures and are not part of our proxy solicitation materials.

 

WHAT DIFFERENTIATES AMNEAL PHARMACEUTICALS?

 

We combine the best of public company accountability, large scale vertical integration and a strong track record of agile execution with a long-term vision for the healthcare industry and Amneal’s leadership role in it. We believe this is a combination that is particularly valuable in the global, affordable medicines sector in these complex and challenging times.

Table
of Contents

 

Corporate Governance	10
Corporate Structure, Reorganization and Transfer of Listing Exchange	10
Stockholders Agreement	10
Code of Business Conduct; Corporate Governance Guidelines; Board Committee Charters	12
Controlled Company Status	12
Board Leadership Structure	12
Meetings of the Board of Directors	13
Communication with the Board of Directors; Director Attendance at Annual Meetings	13
Director Independence	13
Committees of the Board of Directors	14
The Board’s Role in Risk Oversight	16
Director Nominations	17
Director Compensation	18
Proposal 1   Election of Directors	20
Introduction	20
Director Nominees	20
Required Vote	27
Recommendation of the Board of Directors	27
Our Management	28
Executive Officers and Directors	28
Executive Compensation	31
Compensation Discussion and Analysis	31
Executive Summary	31
Role of the Compensation Committee	33
Role of Our Co-Chief Executive Officers in Compensation Decisions	34
Peer Group Surveys and the Role of Our Compensation Consultant	34
Components of Executive Compensation	35
Consideration of 2023 Say-on-Pay Vote	39
Accounting and Tax Considerations	39
Executive Compensation Clawback Policy	39
Stock Ownership Guidelines for Executive Officers	40
Anti-Hedging Policy	40
Report of the Compensation Committee	40
Summary Compensation Table	41
Grants of Plan Based Awards in 2023	42
Outstanding Equity Awards at December 31, 2023	43
2023 Option Exercises and Stock Vested	44
Management Employment & Separation Agreements	44
Severance Plan	46
Potential Payments Upon Termination or Change in Control	47
Pay Ratio Disclosure	49
Pay Versus Performance Disclosure	50
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)	52
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income	53
Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Adjusted EBITDA	54
Tabular List of Most Important Financial Performance Measures	54
Proposal 2   Advisory Vote on Executive Compensation	55
Introduction	55
Required Vote	55
Recommendation of the Board of Directors	55
Security Ownership of Certain Beneficial Owners and Management	56
Beneficial Ownership	56
Certain Related Parties and Related Party Transactions	58
Review and Approval of Related Party Transactions	58
Related Party Transactions	58
Report of the Audit Committee	64
Proposal 3   Appointment of Independent Registered Public Accounting Firm	65
Introduction	65
Independent Registered Public Accounting Firm Fees	65
Required Vote	66
Recommendation of the Board of Directors	66

Other Matters	67
About the Meeting	68
Additional Information	72
Stockholder Proposals for Inclusion in Our 2025 Annual Meeting Proxy Statement and Proxy Card	72
Director Nominations and Other Proposals to Be Presented at Our 2025 Annual Meeting	72
Householding	72
Appendix A Non-GAAP Financial Measures	73
Non-GAAP Financial Measures	73
Reconciliation of Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted EPS	74
Reconciliation of Net Loss to EBITDA and Adjusted EBITDA	75
Reconciliation of Gross Leverage and Net Leverage	76

Safe Harbor Statement

 

Certain statements contained herein, regarding matters that are not historical facts, are forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; the Company’s strategy for growth; product development; regulatory approvals; market position and expenditures, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

 

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the impact of a prolonged business interruption within our supply chain; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in our filings with the Securities and Exchange Commission (the “SEC”), including under Item 1A, “Risk Factors” in our most recent Annual Report on Form 10-K and in our subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Corporate Governance

 

Corporate Structure, Reorganization and Transfer of Listing Exchange

 

The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals LLC (“Amneal LLC”). In 2018, Amneal LLC completed the acquisition of Impax Laboratories, Inc. (“Impax”), a generic and specialty pharmaceutical company (the “Combination”).

 

The group, together with their affiliates and certain assignees, who owned Amneal LLC when it was a private company (the “Amneal Group”) held 50.1% of Amneal Common Units and the Company held the remaining 49.9% as of December 31, 2022. On November 7, 2023, we implemented a plan pursuant to which the Company and Amneal LLC reorganized and we simplified our corporate structure by eliminating our umbrella partnership-C-corporation structure and converting to a more traditional structure whereby all stockholders hold their voting and economic interests directly through the public company (the “Reorganization”). Effective with the Reorganization, the Company directly or indirectly holds 100% of the Amneal Common Units and the Company remains Amneal LLC’s sole managing member, having the sole voting power to make all of Amneal LLC’s business decisions and control its management. Shortly after we effected the Reorganization, at market open on December 27, 2023, we transferred the listing of our Class A common stock to the Nasdaq Stock Market LLC (“Nasdaq”).

 

Stockholders Agreement

 

In connection with the Combination, we entered into a stockholders agreement with the Amneal Group, which was amended and restated in August 2019 and again in November 2023 as part of the Reorganization (the “Stockholders Agreement”), that sets forth, among other things, certain rights and obligations of the Company and the Amneal Group with respect to the corporate governance of the Company.

 

Board Composition

 

The Stockholders Agreement provides that, until the Amneal Group owns less than 10% of the outstanding shares of the Company’s common stock, the Board of Directors of the Company (the “Board”) will consist of no more than 13 members.

 

As of the date hereof, the Board has fixed its size at 11, composed as follows:

 

•	Amneal Group Directors. Six directors, including the Chairman of the Board, were designated by the Amneal Group. The directors designated by the Amneal Group, three of whom qualify as and are considered independent under Nasdaq rules, are referred to herein as the “Amneal Group Directors.”
•	Non-Amneal Group Directors. Five directors were designated as the Company Independent Directors (as defined in the Stockholders Agreement). The directors not designated by the Amneal Group are referred to herein as the “Non-Amneal Group Directors.”

 

Pursuant to, and effective as of, the amendment to the Stockholders Agreement in August 2019, the Amneal Group representative who appoints the Amneal Group Directors will not be (i) an employee of the Company or (ii) an individual controlled, directly or indirectly, by employees of the Company, a Company subsidiary, or any person controlled by the Company. This change was made in connection with the appointment of Chirag Patel and Chintu Patel as co-Chief Executive Officers in order to preserve the independence of those Amneal Group Directors who are intended to be independent.

 

For so long as the Amneal Group continues to beneficially own more than 50% of the outstanding shares of the Company, the Amneal Group Directors will have the right to designate the Chairman or Co-Chairmen of the Board, and the Non-Amneal Group Directors will have the right to designate a lead Independent Director of the Board (as applicable).

 

TPG Group Holdings has the right, subject to certain ownership thresholds and other requirements, to designate a director for appointment to the Company’s Board (which right TPG currently has not exercised) or to designate an observer to the Board.

 

There are currently two observers to the Board, one of whom has been designated by the Board of Directors and one of whom has been designated by TPG Group Holdings.

 

For so long as the Amneal Group continues to beneficially own more than 50% of the outstanding shares of the Company, the Amneal

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		10

Group will have the right to designate for nomination the lowest number of designees that constitute a majority of the total number of directors comprising the Board. The Company will cause such nominee(s) to be included in any slate of nominees recommended by the Board to the stockholders of the Company for election.

 

If the Amneal Group beneficially owns 50% or less but more than 10% of the outstanding shares of the Company, the Amneal Group will have the right to designate a number of directors proportionate to the beneficial ownership of outstanding shares of the Company held by the Amneal Group (rounded up to the nearest whole number); provided, however, that such rounding shall not result in the Amneal Group having the right to designate a majority of the total number of directors comprising the Board when the Amneal Group beneficially owns 50% or less of the outstanding shares of the Company’s common stock.

 

With respect to the Amneal Group Directors, until the date on which the Amneal Group ceases to beneficially own at least 10% of the outstanding shares of the Company (the “Trigger Date”), any vacancy will be filled by the Board with a director designated by the Amneal Group, except when such vacancy is created when the number of the Amneal Group Directors then serving on the Board is in excess of the number of Amneal Group designees the Amneal Group has the right to designate under the Company’s Bylaws and the Stockholders Agreement.

 

With respect to the Non-Amneal Group Directors, the Nominating and Corporate Governance Committee will recommend to the Company’s Board to fill any vacancy (other than the CEO of the Company) with a person who satisfies all the qualifications of a Company Independent Director (as defined in the Stockholders Agreement), subject to the prior written consent of the Conflicts Committee.

 

Board Committees

 

The Stockholders Agreement provides that the Company’s Board shall have the following committees: (i) Audit Committee, (ii) Nominating and Corporate Governance Committee, (iii) Compensation Committee, and (iv) Conflicts Committee. The formation of, composition of, and amendment to the charter of any other committee requires the approval of 75% of the Board.

 

Until the Trigger Date, each committee of the Company’s Board (other than the Conflicts Committee) will include at least one director designated by the Amneal Group, subject to the applicable Nasdaq rules and requirements. If at any time, any committee (other than the Conflicts Committee) does not have at least one such Amneal Group-designated director, the Amneal Group will be entitled to designate a director to have observer rights with respect to such committee.

 

Amneal Group Agreement to Vote

 

Until the Trigger Date, the Amneal Group must cause its shares to be present for quorum purposes at any stockholders meeting, vote in favor of all director nominees recommended by the Company’s Board, and not vote in favor of the removal of any Non-Amneal Group Director, unless such removal is recommended by the Nominating and Corporate Governance Committee.

 

Amneal Group Consent Rights

 

For so long as the Amneal Group beneficially owns more than 25% of the outstanding shares of the Company, the Company will not take the following actions without obtaining prior consent of the Amneal Group:

 

•	amend, modify, or repeal any provision of the Company’s Certificate of Incorporation or Bylaws in a manner that adversely impacts any Amneal Group member;
•	effect any change in the authorized number of directors, except pursuant to the Stockholders Agreement;
•	create or reclassify any new or existing class or series of capital stock to grant rights, preferences, or privileges with respect to voting, liquidation, redemption, conversion or dividends that are senior to or on parity with those of the shares held by the Amneal Group; or
•	consummate any transaction as a result of which (a) more than 50% of the outstanding shares of the Company will be beneficially owned by any persons other than Amneal Group members and (b) any Amneal Group member receives an amount or form of consideration different from that which is granted to other holders of the Company’s shares.

 

Bylaws Amendments

 

As previously disclosed and referenced above, in light of the substantial investment of the Amneal Group prior to the Combination, the Company continues to have certain legacy obligations and corporate governance features that were adopted in connection with the Combination. In particular, the Bylaws that we adopted following the Combination contained a provision requiring the vote of not less than two-thirds of the voting power of the issued and outstanding shares entitled to vote at a duly called and convened annual or special meeting of stockholders in order to amend certain limited Bylaws provisions, including provisions related to stockholder meetings and proposals as well as to the number, term and removal of and nominating

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		11

process for directors. Given the consent rights afforded to the Amneal Group described above pursuant to the Stockholders Agreement, coupled with the continued significant ownership stake of the Company by the Amneal Group, as exemplified by the Company’s designation as a “controlled company” as further discussed below, we expect that this provision will remain in place for the foreseeable future unless otherwise determined by the Amneal Group.

 

Code of Business Conduct; Corporate Governance Guidelines; Board Committee Charters

 

We are committed to conducting every aspect of our business in an ethical, open and honest manner and in full compliance with the law, both in letter and in spirit. Our Code of Business Conduct applies to all of our employees, officers and directors and lays out guidelines for our employees, officers and directors to follow as they conduct business on behalf of our Company. We have also adopted Corporate Governance Guidelines, which, together with our Certificate of Incorporation, Bylaws and Board committee charters, form the framework for the corporate governance of the Company. In addition, the Stockholders Agreement between the Company and the Amneal Group and the limited liability company agreement of Amneal LLC set forth a number of corporate governance requirements with respect to the Company.

 

The full text of the Code of Business Conduct as well as our Corporate Governance Guidelines, Audit Committee Charter, Compensation Committee Charter, Nominating and Corporate Governance Committee Charter and Conflicts Committee Charter are available at the investors section of our web site, http://investors.amneal.com. We intend to satisfy our disclosure obligations, if any, with respect to any amendment to, or waiver from, a provision of the Code of Business Conduct that applies to our directors or executive officers, including our principal executive officers, principal financial officer or principal accounting officer, in the investors section of our web site. Stockholders may request free printed copies of the Code of Business Conduct, Corporate Governance Guidelines and the Board committee charters by writing to: Amneal Pharmaceuticals, Inc., Attention: Corporate Secretary, 400 Crossing Boulevard, Bridgewater, NJ 08807 or corporatesecretary@amneal.com.

 

Controlled Company Status

 

The Amneal Group holds a majority of the voting power of our common stock. As a result, we are a “controlled company” as defined by Nasdaq rules and have the option to elect to avail ourselves of exemptions from certain Nasdaq requirements. Despite our status as a controlled company, however, we have chosen to govern ourselves without using these exemptions, which we believe sets the right tone with respect to our approach to corporate governance. Generally speaking, under Nasdaq rules, a controlled company is exempt from the requirements of (a) a majority of the board of directors consisting of independent directors; (b) independent director oversight of director nominations; and (c) a compensation committee composed entirely of independent directors, with a written charter addressing specified matters. Although we currently do not avail ourselves of any of these exemptions in the interest of corporate governance best practices, if we were to take advantage of any of them, our stockholders would not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq requirements. We believe that the Amneal Group’s control and its long-term stewardship have provided a strategic advantage to our Company. For example, the alignment between our co-CEOs and the Amneal Group as our largest stockholder provides management the flexibility to efficiently pivot as needed to address short-term matters while also supporting transformational changes necessary for the Company’s long-term success. In addition, the Amneal Group’s values have played an important role in our unique work culture that celebrates inclusion, diversity, and equity, which we believe has helped us to attract and retain top talent.

 

Board Leadership Structure

 

Our Board of Directors is led by an independent Chairman. The Chairman’s responsibilities include, but are not limited to, presiding over all meetings of the Board at which members of management are not present, including any executive sessions of independent directors, reviewing Board meeting schedules and agendas and acting as a liaison between the independent directors and the Co-Chief Executive Officers. Our Co-Chief Executive Officers do not hold leadership positions on the Board, but our Corporate Governance Guidelines do not prohibit them from doing so, as the Board retains the discretion to modify its leadership structure in the future as it deems appropriate. The Board has determined that its leadership structure is in the best interests of the Company and our stockholders because it allows our Co-Chief Executive Officers to focus on our day-to-day business and our Chairman to focus on managing Board operations and effectiveness and other corporate governance matters, while providing independent Board leadership.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		12

Meetings of the Board of Directors

 

In the fiscal year ended December 31, 2023 (“fiscal 2023”), the Board of Directors held five meetings. Each of the directors attended at least 75% of the aggregate of all meetings held by the Board of Directors and each committee of the Board of Directors on which he or she served during fiscal 2023, in each case held during the period for which he or she was a director and committee member. Our independent directors meet in executive session at least twice annually. The Chairman presides over executive sessions of the independent directors.

 

Communication with the Board of Directors; Director Attendance at Annual Meetings

 

Stockholders, employees and all other interested parties may communicate with a member or members or a committee of the Board of Directors by addressing their correspondence to the Board member or members or committee c/o Corporate Secretary, Amneal Pharmaceuticals, Inc., 400 Crossing Boulevard, Bridgewater, NJ 08807 or by email to corporatesecretary@amneal. com. Our corporate secretary will review the correspondence and will determine, in his good faith judgment, which stockholder communications will be relayed to the Board of Directors, any committee or any director. Our corporate secretary has the authority to discard or disregard any inappropriate communications or to take other appropriate actions with respect to any such inappropriate communications. Subject to the foregoing, mail addressed to “Board of Directors” or “non-management directors” will be forwarded to the Chairman.

 

Recognizing that director attendance at our annual meetings can provide our stockholders with a valuable opportunity to communicate with Board members about issues affecting our Company, we encourage our directors to attend each annual meeting of stockholders. The 2023 annual meeting was attended by all eleven of the directors holding office at the time.

 

Director Independence

 

In making independence determinations, the Board of Directors observes all criteria for independence established by the SEC, Nasdaq, other governing laws and regulations, and the Stockholders Agreement, and considers all relevant facts and circumstances. In accordance with our Corporate Governance Guidelines, to be considered independent:

 

•	the director must meet the bright-line independence tests under Nasdaq rules; and
•	the Board must affirmatively determine that the director otherwise has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilties of a director.

 

The Board of Directors, through its Conflicts Committee, annually reviews all relevant business relationships any director may have with our Company. As a result of its annual review, the Board has affirmatively determined that each of the following directors meets the independence tests under the Nasdaq rules, none of them has a material relationship with the Company other than their service as directors and, as a result, such directors are independent: Paul Meister, Deb Autor, J. Kevin Buchi, Jeff George, John Kiely, Ted Nark, Emily Peterson Alva and Shlomo Yanai. Accordingly, even though we are a “controlled company” and therefore exempt from certain board independence requirements under the Nasdaq rules, we nonetheless have a majority of independent directors on our Board, and each Board committee is comprised entirely of independent directors.

 

In making the foregoing independence determination, the Board of Directors considered the following relationship in light of the Company’s independence standards and determined that it does not constitute a material relationship with the Company:

 

Emily Peterson Alva’s spouse was employed by Avtar Investments, LLC (“Avtar”), a financial advisory firm that manages investments for Chirag Patel and Chintu Patel, each a member of the Amneal Group and Co-CEOs of the Company. Ms. Alva’s spouse is no longer affiliated with Avtar.

 

In addition to the director independence standards described above, the Stockholders Agreement imposes additional independence requirements that apply in certain circumstances. The Stockholders Agreement defines a “Company Independent Director” as a director who:

 

•	meets the independence standards under the rules of Nasdaq;
•	is a non-Amneal Group Director;
•	is not a current or former member of the Board of Directors of any Amneal Group member or its affiliates or officer or employee of any Amneal Group member or its affiliates;
•	does not have and has not had any other material relationship with the Company or its affiliates; and
•	is designated as a “Company Independent Director.”

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		13

Committees of the Board of Directors

 

The Board of Directors has four standing committees: an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee, and a Conflicts Committee.

 

The following table sets forth the current members of each committee and the number of meetings held during fiscal 2023 for each of the Board’s committees, as well as each director’s status as either independent or not independent and either an Amneal Group Director or Non-Amneal Group Director.

 

Independent

Amneal Group Director

Non-Amneal Group Director

Audit Committee

Compensation Committee

Nominating and Corporate Governance Committee

Conflicts Committee

Emily Peterson Alva

Deb Autor

J. Kevin Buchi

Chair

Jeff George

John Kiely

Chair

Paul Meister

Chair

Ted Nark

Chair

Chintu Patel

Chirag Patel

Gautam Patel

Shlomo Yanai

# of Meetings in 2023

5

5

4

15

 

Audit Committee

 

The principal duties and responsibilities of our Audit Committee are to assist the Board in its oversight of:

 

•	the quality and integrity of the Company’s financial statements;
•	the Company’s compliance with legal and regulatory requirements;
•	the implementation of the Company’s enterprise risk management program and policies with respect to risk assessment and risk management, including cyber risks and information security;
•	the independent auditor’s qualifications, performance and independence; and
•	the performance of the Company’s internal audit function.

 

The Audit Committee has the power to investigate any matter brought to its attention within the scope of its duties. It also has the authority to retain counsel and advisors to fulfill its responsibilities and duties. Each director who serves on the Audit Committee is independent under the Nasdaq rules and as that term is used in Section 10A(m)(3) of the Securities Exchange Act of 1934, as amended. The Board of Directors has determined that each member of the Audit Committee meets the financial sophistication requirements of Nasdaq. Further, the Board of Directors has determined that John Kiely qualifies as an Audit Committee financial expert as that term is defined by applicable SEC regulations and has designated Mr. Kiely as the Audit Committee’s financial expert.

 

The Audit Committee operates under a written charter adopted by the Board of Directors. A copy of the charter is available at the investor relations section of our website at https://investors. amneal.com/corporate-governance/policies. The report of the Audit Committee begins on page 64 of this proxy statement.

 

Compensation Committee

 

The principal duties and responsibilities of the Compensation Committee are as follows:

 

•	review and oversee the Company’s overall compensation philosophy and oversee the development and implementation of compensation programs aligned with the Company’s business strategy;
•	review and make recommendations to the Board in overseeing the compensation of the Company’s directors and Co-Chief Executive Officers and review and approve the compensation of the Company’s other executive officers;
•	review and approve or make recommendations to the Board regarding the Company’s annual cash incentive program and equity-based plan and arrangements;

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		14

•	review and discuss with management the Company’s “Compensation Discussion and Analysis” (“CD&A”) and recommend whether such analysis should be included in the Proxy Statement filed with the SEC;
•	produce an annual report on executive compensation for inclusion in the Company’s Proxy Statement;
•	review and discuss the results of the stockholder advisory vote on “say-on-pay”, if any, and general market reactions to executive compensation regard to the Company’s named executive officers;
•	review and approve any stock ownership guidelines for directors and executive officers of the Company and monitor complaiance therewith;
•	review and approve any “clawback” policy to be adopted by the Company to recoup compensation paid to employees, if and as the committee determines to be necessary or appropriate, or as required by applicable law or Nasdaq requirements, and monitor compliance therewith;
•	oversee the Company’s policies and practices with respect to managing compensation-related risks;
•	oversee and approve the management continuity process; and otherwise comply with the committee’s responsibilities and duties as set forth in its charter.

 

Each director who serves on the Compensation Committee is independent under the Nasdaq rules and applicable SEC regulations with respect to Compensation Committees. In addition to satisfying all other applicable independence requirements, all members of the Compensation Committee qualify as “non-employee directors” for purposes of Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Compensation Committee operates under a written charter adopted by the Board of Directors, a copy of which is available at the investor relations section of our website at https://investors.amneal.com/corporate-governance/ policies. The report of the Compensation Committee is on page 40 of this proxy statement.

 

Pursuant to the Stockholders Agreement, the Amneal Group has the right to nominate two of the four directors serving on the Compensation Committee for so long as the Amneal Group beneficially owns more than 50% of the outstanding shares of the Company. The remaining directors are designated by a majority of the Company Independent Directors of the Company’s Board.

 

Nominating and Corporate Governance Committee

 

The principal duties and responsibilities of the Nominating and Corporate Governance Committee are as follows:

 

•	identify individuals qualified to become Board members consistent with the criteria approved by the Board;
•	recommend to the Board director nominees for election by stockholders;
•	take leadership role in overseeing management’s handling of ESG matters of importance to the Company;
•	develop and recommend to the Board a set of Corporate Governance Guidelines; and
•	oversee the evaluation of the Board and management.

 

Each director who serves on the Nominating and Corporate Governance Committee is independent under the Nasdaq rules. The Nominating and Corporate Governance Committee operates under a written charter adopted by the Board of Directors, a copy of which is available at the investor relations section of our website at https://investors.amneal.com/corporate-governance/policies.

 

Pursuant to the Stockholders Agreement, the Amneal Group has the right to nominate two of the four directors serving on the Nominating and Corporate Governance Committee for so long as the Amneal Group beneficially owns more than 50% of the outstanding shares of the Company. The remaining directors are designated by a majority of the Company Independent Directors of the Company’s Board.

 

Conflicts Committee

 

The principal duties and responsibilities of the Conflicts Committee are to provide leadership and guidance to the Board and the Company regarding transactions or situations involving potential conflicts of interest between the Company and its related parties. The responsibilities of the Conflicts Committee include approval of certain transfers of shares of the Company by an Amneal Group member to third parties, approval of qualifying related party transactions, and approval of any material amendment to the Stockholders Agreement, as set forth in the Conflicts Committee Charter.

 

The Conflicts Committee operates under a written charter adopted by the Board of Directors, a copy of which is available at the investor relations section of our website https://investors. amneal.com/corporate-governance/policies.

 

Pursuant to the Stockholders Agreement, until the Trigger Date, the Board will have a Conflicts Committee comprised solely of Company Independent Directors. Any amendments to the Conflicts Committee Charter will be approved by (i) 75% of the directors of the Company’s Board, (ii) a majority of the Company Independent Directors, and (iii) a majority of the Conflicts Committee.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		15

The Board’s Role in Risk Oversight

 

Management is responsible for managing the day-to-day risks our Company faces. Our Board is responsible for:

 

•	confirming that management has implemented an appropriate system to manage these risks, i.e., to identify, assess, mitigate, monitor and communicate about these risks; and
•	providing effective risk oversight through the Board’s committee structure and oversight processes.

 

Beyond these fundamental responsibilities for risk oversight, our Board concentrates on the broader implications of our strategic plans and allows the committees to focus on specific areas of risk. Our directors, through their risk oversight role, are responsible for confirming that the risk management processes designed and implemented by the Company’s executive officers and other senior managers are consistent with the Company’s corporate strategy and are functioning as intended.

 

The Board believes that full and open communication between management and the Board of Directors is essential for effective risk management and oversight. In addition to making quarterly presentations at our quarterly Board meetings, our executive officers are available to discuss any questions or concerns raised by the Board relating to risk management and any other matters. In addition, management typically reports on cybersecurity matters to our Audit Committee twice a year.

 

Audit Committee

 

In accordance with its charter, the Audit Committee is required to, among other things, focus on the reasonableness of control processes for identifying and managing key business, financial and regulatory reporting risks. The Audit Committee is also mandated by its charter to discuss with management our Company’s major financial risk exposures and the steps management has taken to monitor and control such exposures, including our risk assessment and risk management policies. The Audit Committee monitors our Company’s credit risk, liquidity risk, regulatory risk, operational risk and enterprise risk through regular reviews with management, external auditors and our Company’s internal audit function. The Audit Committee reviews and discusses with management the implementation, execution and performance of the Company’s enterprise risk management program and the strategies, processes and controls pertaining to the management of the company’s information technology operations, including cyber risks and information security.

 

Compensation Committee

 

The Compensation Committee assists the Board in fulfilling its oversight responsibilities with respect to the evaluation and management of risks arising from our compensation policies and programs. The Compensation Committee has reviewed our incentive compensation programs, discussed the concept of risk as it relates to our compensation program, considered various mitigating factors and reviewed these items with its independent consultant, Meridian Compensation Partners, LLC (“Meridian”).

 

In addition, our Compensation Committee asked Meridian to conduct an independent risk assessment of our executive compensation program. Based on these reviews and discussions, the Compensation Committee does not believe our compensation program creates risks that are reasonably likely to have a material adverse effect on our business.

 

Nominating and Corporate Governance Committee

 

The Nominating and Corporate Governance Committee assists the Board in fulfilling its oversight responsibilities with respect to the management of risks associated with corporate governance, including Board structure, size, membership and succession planning for our directors, as well as ESG matters of importance to the Company. The Committee also assists in carrying out the Company’s commitment to ESG principles and diverse representation on its Board.

 

Conflicts Committee

 

The Conflicts Committee assists the Board in fulfilling its oversight responsibilities with respect to the management of the risks associated with the conflicts of interest that may arise from certain related party transactions.

 

Cybersecurity

 

While the Board is ultimately responsible for risk oversight, committees of the Board assist in fulfilling the oversight responsibilities of the Board in certain areas of risk. Our Audit Committee is responsible for overseeing risks from cybersecurity threats and receives cybersecurity updates from Information Technology (“IT”) leadership at least twice a year. When meeting with the Audit Committee, the IT leadership team highlights significant accomplishments and issues related to our IT infrastructure, including cybersecurity incidents, risks, industry trends, notable incidents facing other companies, incident preparedness and other developments. The Audit Committee also receives updates regarding progress on initiatives to further align with the five pillars of the NIST CSF. These briefings are designed to provide visibility to the Audit Committee about the identification, assessment, and management of critical risks, audit findings, and management’s risk mitigation strategies. Our global head of Cybersecurity, who reports to our CFO, participates in H-ISAC (Health Information Sharing and Analysis Center), a global community and member forum for coordinating, collaborating and sharing vital Physical and Cyber Threat Intelligence and best practices with each other. Our Board also receives regular quarterly updates from our Vice President of Corporate Compliance who reports to our Chief Legal Officer.

 

We administer multiple cybersecurity related training and awareness events annually. Our user awareness training program includes baseline cybersecurity training for all new employees and an annual mandatory interactive cybersecurity training

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		16

for all employees and contingent workers, as well as multiple cybersecurity topic awareness broadcast emails and targeted training to specific user groups. We employ a third party to conduct periodic penetration testing to scan different parts of the Company’s IT environment to identify potential vulnerabilities. Critical or high vulnerabilities are prioritized for swift remediation. Additionally, we employ a third-party service for continuous cyber risk monitoring and make continuous adjustments to system and network configurations to improve our cyber risk rating score. For further information related to our cybersecurity risk management process and identified cybersecurity risks, please refer to Part I, Item 1C of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

 

Director Nominations

 

The Nominating and Corporate Governance Committee considers recommendations for directorships submitted by our stockholders on a substantially similar basis as it considers other nominees. Stockholders who wish the Nominating and Corporate Governance Committee to consider their recommendations for nominees for the position of director should submit their recommendations, in accordance with the procedures (including the information requirements) set forth in our Bylaws, in writing to: Corporate Secretary, Amneal Pharmaceuticals, Inc., 400 Crossing Boulevard, Bridgewater, NJ 08807. For the Nominating and Corporate Governance Committee to have adequate time to consider such candidate, the stockholder’s notice should be received at the address above within the time period set forth in our Bylaws (see “Director Nominations and Other Proposals to Be Presented at Our 2025 Annual Meeting” below).

 

In its assessment of each potential candidate, the Nominating and Corporate Governance Committee reviews the nominee’s personal and professional integrity, ethics and values and ability to make mature business decisions. The Nominating and Corporate Governance Committee may also consider the following criteria, as well as any other factor the committee deems relevant:

 

•	the candidate’s experience in corporate management, such as serving as an officer of a publicly held company;
•	the candidate’s experience as a board member of a publicly held company;
•	the candidate’s professional and academic experience relevant to our industry;
•	the strength of the candidate’s leadership skills;
•	the candidate’s experience in finance and accounting and executive compensation practices;
•	diversity of viewpoints, background, experience and other demographics; and
•	whether the candidate has the time required for the preparation, participation and attendance at board and committee meetings.

 

Nominees may also be recommended by directors, members of management, or, in some cases, by a third-party firm. In identifying and considering candidates for nomination to the Board, the Nominating and Corporate Governance Committee may consider, in addition to the requirements described above and set out in its charter, quality of experience, our needs and the range of knowledge, experience and diversity represented on the Board. Each director candidate is evaluated by the Nominating and Corporate Governance Committee based on the same criteria and in the same manner, regardless of whether the candidate was recommended by a stockholder or by others.

 

The Board of Directors does not have a formal policy on Board diversity as it relates to the selection of nominees for the Board. That said, the Board believes that diversity and a variety of experiences and viewpoints should be represented on the Board. In selecting a director nominee, the Nominating and Corporate Governance Committee focuses on skills, viewpoints, expertise or background that would complement the existing Board. The Nominating and Corporate Governance Committee regularly assesses the composition of the Board and seeks to identify candidates representing diverse experience at policy-making levels in business, management, marketing, finance, human resources, communications and other areas that are relevant to our activities. In addition, one of the many factors that the Board and the Nominating and Corporate Governance Committee carefully considers is the importance to the Company of ethnic and gender diversity. The Nominating and Corporate Governance Committee assesses its effectiveness in this regard when evaluating the composition of the Board.

 

In the case of a recommendation submitted by a stockholder, after full consideration, the stockholder proponent will be notified of the decision of the Nominating and Corporate Governance Committee.

 

The Nominating and Corporate Governance Committee conducts the appropriate and necessary inquiries with respect to the backgrounds and qualifications of all director nominees. Diversity is essential to Amneal’s success. It starts at the top, with six out of ten of our executives identifying as diverse by race, ethnicity, or gender, and permeates through the organization of Amneal employees. In 2023, women represented 19% of our global workforce of Amneal employees. In the United States, they represented 41% of our workforce and held 32% of leadership roles at the level of Director and above for Amneal employees. Approximately 74% of our U.S. workforce of Amneal employees identified as diverse by race or ethnicity. The Nominating and Corporate Governance Committee also reviews the independence of each candidate and other qualifications of all director candidates, as well as considers questions of possible conflicts of interest between director nominees and our Company. After the Nominating and Corporate Governance Committee has completed its review of a nominee’s qualifications and conducted the appropriate inquiries, the Nominating and Corporate Governance Committee makes a determination whether to recommend the nominee for approval by the Board of Directors. If the Nominating and Corporate Governance Committee decides to recommend the director nominee for nomination by the Board of Directors and such recommendation is accepted by the Board, the form of our proxy solicitation will include the name of the director nominee.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		17

Board and Organizational Diversity

 

The Company also places a high priority on creating a Board that reflects expanded experiences and perspectives, including experiences and perspectives arising out of diversity related to race, ethnicity, gender, sexual orientation and areas of expertise. Consistent with this philosophy, our Board reflects a mix of ethnic, sexual orientation and gender diversity. As set forth in the matrix below, of our 11 Board members, ten have disclosed their gender and demographic backgrounds, which consists of eight male and two female Board members, with three Board members who identify as Asian, seven who identify as white and one who identifies as LGBTQ+.

 

Board Diversity Matrix (As of March 11, 2024)
Board Size:
Total Number of Directors:						11
		Female		Male		Non-Binary		Did not Disclose Gender
Gender:
Directors:		2		8				1
Number of Directors who Identify in Any of the Categories Below:
Asian				3
White		2		5
LGBTQ+						1

 

Director Compensation

 

Each of our non-employee directors receives an annual fee payable in cash. In addition, so that our non-employee directors have an ownership interest aligned with our stockholders, each non-employee director also receives an annual grant of restricted stock units. Board members also receive an initial equity grant when they join the Board. Members of our Board committees receive an additional annual fee for each committee on which they serve. In addition to the annual grant of restricted stock units that all non-employee directors are eligible to receive, our Chairman receives an additional annual award of restricted stock units with a grant date fair value of $100,000 in connection with his increased duties. From time to time, the Compensation Committee reviews the compensation of our non-employee directors with our independent compensation consultant and makes recommendations to the Board with respect to any changes; our non-employee director compensation program was last reviewed in May 2023. In connection with this update, and as recommended by the independent compensation consultant based on market practices, no changes were made to the non-employee director compensation. No changes were made to our non-employee director compensation structure during 2023 other than the use of a 12-month average stock price over 2022 in setting the grant price for all equity awards to directors. This 2022 12-month average stock price was $3.27, as compared to an actual date of grant closing price of $1.86. Consequently, grant date fair values for awards to non-employee directors were only 57% of targeted values. The Company expects to revert back to its historic methodology of using the closing market price of our common stock on the date of grant for setting the grant price with respect to future equity grants to non-employee directors. This change in setting the grant price was made in order to align with grant price methodology used for awards made to NEOs and eligible employees.

 

Our director compensation program is summarized in the table below.

 

Annual Cash Retainer		$75,000
Annual Equity Grant
Restricted stock units (target value)		$250,000/$350,000 for Chairman
Vesting Schedule		1 year cliff vesting
Additional Cash Fees for Committee Service
Audit Committee (Chair/Member)		$25,000/$15,000
Compensation Committee (Chair/Member)		$20,000/$10,000
Nominating and Corporate Governance Committee (Chair/Member)		$15,000/$7,500
Conflicts Committee (Chair/Member)		$25,000/$15,000

 

In addition to the annual retainers described above, for each duly convened meeting of a committee that a member of such committee attends in excess of six duly convened meetings per calendar year, such member shall be entitled to receive an additional Per Meeting Stipend equal to 1/6^th of such member’s annual cash stipend for service on that committee.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		18

During fiscal 2023, our non-employee directors received the following compensation:

 

Name		Fees Earned or Paid in Cash			Stock Awards(10)			Total
Emily Peterson Alva(1)		$	75,000		$	142,203		$	217,203
Deborah Autor(2)		$	124,833		$	142,203		$	267,036
J. Kevin Buchi(3)		$	160,000		$	142,203		$	302,203
Jeff George(4)		$	135,000		$	142,203		$	277,203
John Kiely(5)		$	142,500		$	142,203		$	284,703
Paul Meister(6)		$	100,000		$	199,083		$	299,083
Ted Nark(7)		$	102,500		$	142,203		$	244,703
Gautam Patel(8)		$	75,000		$	142,203		$	217,203
Shlomo Yanai(9)		$	112,500		$	142,203		$	254,703

(1)	As of December 31, 2023, Ms. Alva had 76,453 RSUs outstanding and 53,021 options outstanding.
(2)	As of December 31, 2023, Ms. Autor had 76,453 RSUs outstanding.
(3)	As of December 31, 2023, Mr. Buchi had 76,453 RSUs outstanding and 81,397 options outstanding.
(4)	As of December 31, 2023, Mr. George had 76,453 RSUs outstanding and 28,506 options outstanding.
(5)	As of December 31, 2023, Mr. Kiely had 76,453 RSUs outstanding and 28,506 options outstanding.
(6)	As of December 31, 2023, Mr. Meister had 107,034 RSUs outstanding and 115,156 options outstanding.
(7)	As of December 31, 2023, Mr. Nark had 76,453 RSUs outstanding and 53,021 options outstanding.
(8)	As of December 31, 2023, Mr. Patel had 76,453 RSUs outstanding and 53,021 options outstanding.
(9)	As of December 31, 2023, Mr. Yanai had 76,453 RSUs outstanding and 28,506 options outstanding.
(10)	For equity grants made to our non-employee directors in 2023, the Company utilized the 2022 12-month stock price average in setting the grant price. This 2022 12-month average stock price was $3.27, as compared to an actual date of grant closing price of $1.86. Consequently, grant date fair values for awards to non-employee directors were only 57% of targeted values. The Company expects to revert back to its historic methodology of using the closing market price of our common stock on the date of grant for setting the grant price with respect to future equity grants to non-employee directors.

 

Employee directors do not receive any separate compensation for their Board activities. Prior to their appointment in August 2019 as Co-Chief Executive Officers, Chintu Patel and Chirag Patel received compensation for their service as non-employee directors in accordance with the program described above. Following these appointments, they no longer receive compensation for service as directors. See “Compensation Discussion and Analysis” beginning on page 31 for information about their compensation as Co-Chief Executive Officers.

 

Director Stock Ownership Guidelines

 

In order to further align the interests of our non-employee directors with the interests of our stockholders, we require our non-employee directors to own our stock as set forth below.

 

Position	Minimum Ownership Guideline
Non-employee directors	3x annual cash retainer

 

We adopted our stock ownership guidelines in May 2018, as amended in April 2022, and we expect our non-employee directors to be able to achieve the required ownership thresholds by five years from the date of adoption of the guidelines. Newly elected directors will have five years from the date of their appointment or election. For the purpose of determining stock ownership levels, we include shares owned directly or by immediate family members residing in the same household (or through trusts for their benefit), underlying restricted stock and restricted stock units (whether or not vested) but exclude shares underlying unexercised option awards and unearned performance awards. All of our non-employee directors have achieved the minimum ownership thresholds or are working towards compliance within five years from the date or their appointment or election.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		19

Proposal 1 Election of Directors

 

Introduction

 

Our Company’s Bylaws provide for the annual election of directors. Upon the recommendation of our Nominating and Corporate Governance Committee, our Board has nominated for election each of our current directors.

 

At the annual meeting, the 11 nominees for director are to be elected to hold office until the next annual meeting of stockholders and until their successors have been elected and qualified. Each of the nominees has consented to serve as a director if elected. If any of the nominees shall become unable or unwilling to stand for election as a director (an event not now anticipated by the Board), proxies will be voted for such substitute as designated by the Board, or, alternatively, the Board may reduce the number of directors on the Board, subject to the provisions of the Stockholders Agreement.

 

Director Nominees

 

For each of the 11 director nominees standing for election, the following sets forth certain biographical information, including a description of their business experience during at least the past five years and the specific experience, qualifications, attributes or skills that qualify them to serve as directors of the Company and/or members of the Board committees on which they serve. All eleven nominees were previously elected by stockholders at the 2023 annual meeting.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		20

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		21

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		22

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		23

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		24

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		25

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		26

Required Vote

 

Our Bylaws provide for a majority vote standard in uncontested elections of directors. Therefore, to be elected at our 2024 annual meeting, which is an uncontested election, each nominee for director must receive the affirmative vote of the majority of the votes cast with respect to such nominee by the holders of the shares of common stock voting in person, by remote communication or by proxy at the annual meeting. A majority of the votes cast means that the number of votes cast “for” a nominee must exceed the number of votes cast “against” that nominee.

 

Recommendation of the Board of Directors

 

THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” EACH OF THE BOARD OF DIRECTORS’ NOMINEES SET FORTH IN PROPOSAL NO. 1.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		27

Our Management

 

Executive Officers and Directors

 

Our executive officers and directors, their positions and their ages as of March 11, 2024, are as set forth in the table below. Each of our directors holds office until the next annual meeting of our stockholders or until his or her successor has been elected and qualified. Our executive officers serve at the discretion of the Board of Directors.

 

Name		Age		Position
Chintu Patel		52		Co-Chief Executive Officer, Director
Chirag Patel		57		Co-Chief Executive Officer and President, Director
Andrew Boyer		58		Executive Vice President, Chief Commercial Officer-Generics
Anastasios Konidaris		57		Executive Vice President, Chief Financial Officer
Jason B. Daly		50		Senior Vice President, Chief Legal Officer and Corporate Secretary
Nikita Shah		46		Executive Vice President, Chief Human Resources Officer
Paul Meister		71		Chairman of the Board of Directors
Emily Peterson Alva		49		Director
Deb Autor		57		Director
J. Kevin Buchi		68		Director
Jeff George		50		Director
John Kiely		65		Director
Ted Nark		65		Director
Gautam Patel		51		Director
Shlomo Yanai		71		Director

 

For a description of the business experience of the above individuals who are director nominees standing for election, see “Proposal No. 1-Election of Directors.”

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		28

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		29

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		30

Executive Compensation

 

Compensation Discussion and Analysis

 

The following Compensation Discussion and Analysis contains statements regarding historical and future Company performance targets or goals. We have disclosed these targets or goals in the limited context of our compensation programs and they should not be understood to be statements of management’s expectations or estimates of results. We specifically caution investors not to apply these statements to other contexts.

 

	TABLE OF CONTENTS
	Executive Summary		31
	Role of the Compensation Committee		33
	Role of Our Co-Chief Executive Officers in Compensation Decisions		34
	Peer Group Surveys and the Role of Our Compensation Consultant		34
	Components of Executive Compensation		35
	Base Salaries		35
	Annual and Long-Term Incentive Awards		35
	Annual Performance-Based Cash Incentive Compensation		36
	Long-Term Incentive Compensation		37
	Other Compensation and Benefits		39
	Executive Severance and Change in Control Severance Benefits		39
	Consideration of 2023 Say-on-Pay Vote		39
	Accounting and Tax Considerations		39
	Executive Compensation Clawback Policy		39
	Stock Ownership Guidelines for Executive Officers		40
	Anti-Hedging Policy		40
	Report of the Compensation Committee		40

 

Executive Summary

 

In the paragraphs that follow, we provide an overview and analysis of our compensation programs and policies, the material compensation decisions we have made under those programs and policies, and the material factors that we considered in making those decisions. Following this section, you will find a series of tables containing specific information about the compensation earned or paid in fiscal 2023 to the following executive officers:

 

2023 NAMED EXECUTIVE OFFICERS

 

Name	Position
Chirag Patel	Co-Chief Executive Officer and President
Chintu Patel	Co-Chief Executive Officer
Anastasios Konidaris	Executive Vice President and Chief Financial Officer
Andrew Boyer	Executive Vice President, Chief Commercial Officer - Generics
Nikita Shah	Executive Vice President, Chief Human Resources Officer
Jason Daly	Senior Vice President, Chief Legal Officer and Corporate Secretary

 

Throughout this proxy statement we refer to these individuals as our “named executive officers” or “NEOs.” The discussion below is intended to help you understand the detailed information provided in those tables and put that information into context within our overall compensation program.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		31

The primary objective of our executive compensation program is to provide compensation designed to:

 

•	attract, motivate and retain executive officers of outstanding ability and potential;
•	reinforce the execution of our business strategy and the achievement of our business objectives; and
•	align the interests of our executive officers with the interests of our stockholders, with the ultimate objective of increasing stockholder value.

 

The Compensation Committee aims to provide incentives for performance in a given year and over a sustained period by paying reasonable and competitive compensation, and by basing a significant portion of our total compensation package upon achieving that performance (i.e., “pay for performance”).

 

We also aim for simplicity in our compensation program so that it is easy for our employees and our stockholders to understand the various components of our compensation program and the incentives designed to drive Company performance. The three key components of our executive compensation program are base salary, annual cash performance-based incentive and equity-based long-term incentive awards.

 

We believe that the compensation program has been instrumental in helping the Company achieve financial and strategic goals, as evidenced by the following:

 

2023 Financial Performance and Operational Execution

 

We are a diversified and growing pharmaceutical company across each of our three business segments, Generic (which includes Retail, Injectables and Biosimilars), Specialty and AvKARE both in the U.S. and Internationally. Our Company’s mission centers on improving access to affordable, high-quality, and innovative medicines across these areas. 2023 was a robust year of growth, outstanding execution, and further diversification of our business as we expanded into new high growth areas. During 2023, we:

 

•	Launched 39 new Generics products as the portfolio continues to shift towards more complex, non-oral solid products;
•	Successfully commercialized our first three biosimilars, ALYMSYS®, RELEUKO® and FYLNETRA®, in their first year post launch, and added two biosimilars to the pipeline;
•	Received approval for a number of high-value injectable products as we further expand our injectables portfolio;
•	Delivered continued growth in key Specialty products, including RYTARY® and UNITHROID®, added ONGENTYS® to expand our portfolio, and continued to advance our Specialty pipeline, including IPX203 for the treatment of Parkinson’s Disease;
•	Drove continued, strong double-digit growth in our durable AvKARE distribution business in the U.S.; and
•	Expanded our international presence as we launched three new business areas in India: Opthalmology, Diagnostics and Oncology, received approval for our first products in China and finalized numerous global partnerships for distributing our medicines

 

These achievements contributed to strong 2023 performance, highlighted by revenue growth of 8.0% and Adjusted EBITDA growth of 8.6%, in both cases as compared to 2022, and reflects durable growth as both top and bottom-line metrics have grown consistently each year since 2019.

 

The Company’s balance sheet is strong as we successfully refinanced our debt and extended maturities to 2028. In addition, during 2023, we reorganized our corporate structure which is expected to drive significant cash savings for the Company. Furthermore, we finished 2023 with net leverage of 4.8x, which is down from 7.4x in 2019. We look to achieve our target of below 4.0x net leverage in 2025.

 

		Full-Year 2023 Results*				Full-Year 2022 Results*
Net Revenue		$	2,394			$	2,212
Net Loss		$	(84	)		$	(130	)
Diluted EPS		$	(0.48	)		$	(0.86	)
Adjusted Net Income		$	198			$	208
Adjusted EBITDA		$	558			$	514
Adjusted Diluted EPS		$	0.64			$	0.68

*	In millions, except per share data

 

Adjusted net income, adjusted EBITDA, adjusted diluted EPS and net leverage are not financial measures in conformity with U.S. generally accepted accounting principles (“GAAP”). Please see “Appendix A – Non-GAAP Measures” for more information, including reconciliations to the most directly comparable GAAP measures along with an explanation for why we use these measures and how they are useful to investors.

 

Amneal delivered positive TSR for the year on a percentage basis, exceeding the Russell 2000 Index, Nasdaq Composite Total Return Index and Dow Jones U.S. Select Pharmaceuticals Index during 2023. Set forth below is a line graph comparing the change in the cumulative total shareholder return on our Class A common stock with the cumulative total returns of the Nasdaq Composite Total Return Index, the Russell 2000 Index and the Dow Jones U.S. Select Pharmaceuticals Index for the period from December 31, 2018 to December 31, 2023, assuming the investment of $100 on December 31, 2018, and the reinvestment of dividends.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		32

Comparison of Cumulative Five Year Total Return

 

 

Role of the Compensation Committee

 

The Compensation Committee of our Board of Directors is responsible for setting and administering the policies that govern salary, annual and long-term incentive programs and other compensation and benefits for our executive officers. The Compensation Committee annually evaluates the performance of, and evaluates the compensation of, our Co-Chief Executive Officers based upon a combination of the achievement of corporate goals and individual performance. As part of its performance review process, the Compensation Committee solicits the input of the full Board of Directors and makes recommendations to the full Board, which makes compensation decisions with respect to our Co-Chief Executive Officers on the basis of those recommendations. The Compensation Committee oversees various executive and employee compensation plans and programs, and it has responsibility for continually monitoring these plans and programs to confirm that they adhere to our compensation philosophy and objectives. Our Compensation Committee determines the appropriate compensation levels of executives, evaluates officer and director compensation plans, policies and programs, and reviews benefit plans for officers. Our Compensation Committee believes that the total compensation paid to our named executive officers should be reasonable and competitive, and that a significant portion of the total compensation should be tied to our Company’s annual and long-term performance.

 

The Compensation Committee has the authority to engage the services of outside advisers, experts and others to assist the Compensation Committee, and believes that it is important to do so from time to time. See “Peer Group Surveys and the Role of Our Compensation Consultant” below.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		33

Role of Our Co-Chief Executive Officers in Compensation Decisions

 

Regarding most compensation matters, including executive compensation and our annual and long-term incentive plans, Chirag Patel, our Co-Chief Executive Officer and President, and Chintu Patel, our Co-Chief Executive Officer, evaluate the performance of our other executive officers and make recommendations to the Compensation Committee on the basis of these reviews, including with respect to salary adjustments and incentive plan award amounts for the other executive officers. The Compensation Committee, however, does not delegate any of its functions to others in setting compensation for our named executive officers and exercises its judgment to make final compensation determinations.

 

Neither of the Co-Chief Executive Officers participates in the decision making regarding his own compensation. Our Compensation Committee reports the compensation decisions it has made with respect to our executive officers other than our Co-Chief Executive Officers to the Board of Directors.

 

Peer Group Surveys and the Role of Our Compensation Consultant

 

The Compensation Committee engages an independent compensation consultant who acts as a strategic advisor to the Compensation Committee, providing objective analysis and expertise on matters related to executive compensation programs and governance. Since 2022, the Compensation Committee has engaged Meridian as the committee’s independent compensation consultant.

 

Each year the Compensation Committee reviews and evaluates the independence of its compensation consultant and considers several factors in determining their independence. For 2023, the Compensation Committee evaluated the following factors in determining Meridian’s independence:

 

•	Meridian’s services are limited to their scope of work as the Compensation Committee’s independent compensation consultant.
•	The fees paid to Meridian represented less than 1% of Meridian’s total annual revenue.
•	Meridian maintains policies and procedures which are designed to prevent conflicts of interest including a Code of Business Conduct and Ethics Policy as well as an Insider Trading and Stock Ownership Policy.
•	There were no business or personal relationships between Meridian’s individual compensation advisor with any Compensation Committee member nor any executive officer of the Company.

 

Further, in assessing Meridian’s independence from management in providing executive compensation services to the Compensation Committee, the Compensation Committee considered that Meridian is only engaged by, takes direction from, and reports to, the Compensation Committee and only the Compensation Committee has the right to terminate or replace Meridian as its compensation consultant. For 2023, the Compensation Committee evaluated whether any work provided by Meridian raised any conflict of interest and, based on the foregoing, determined that it did not.

 

Peer Group Companies and Survey Data

 

Our Compensation Committee finds comparative data from our peer group to be helpful in setting and adjusting executive compensation, but it does not target our programs or any particular element of compensation to be at or within a particular percentile or range compared to our peers. Our Compensation Committee uses the peer group data along with other relevant compensation survey sources to ensure that our executive compensation program and its constituent elements are and remain competitive in relation to our peers, and applies judgment and discretion in establishing targeted compensation levels taking into account not only competitive market data but also the experience of the executive, scope of responsibility, critical skill sets and expertise.

 

The Compensation Committee reviews the composition of our peer group annually to ensure that the companies constituting the peer group continue to provide meaningful and relevant compensation comparisons, including representation from appropriate industries, financial metric comparisons (such as revenue, EBITDA, market capitalization and financial growth), number of employees and location. With respect to the composition of the peer group used to evaluate 2023 executive compensation, the Compensation Committee also sought representation from companies with generic, specialty and biosimilar products as our own mix of products across these categories continues to evolve. In September of 2022, in consideration of these factors and the recommendation of its independent compensation consultant, the Compensation Committee removed OPKO Health and added ANI Pharmaceuticals, Inc., Coherus BioSciences, Inc., Eagle Pharmaceuticals, Inc., Mallinckrodt plc, Neurocrine Biosciences, Inc., Organon & Co, Pacira BioSciences, Inc., Teva Pharmaceutical Industries Limited and Viatris Inc. to the 2023 compensation peer group.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		34

Our 2023 peer group consisted of the following publicly traded companies:

 

•  Alkermes plc		•  Mallinckrodt plc*
•  Amphastar Pharmaceuticals, Inc.		•  Neurocrine Biosciences, Inc.*
•  ANI Pharmaceuticals, Inc.*		•  Organon & Co.*
•  Coherus BioSciences, Inc.*		•  Pacira BioSciences, Inc.*
•  Eagle Pharmaceuticals, Inc.*		•  Perrigo Company plc
•  Emergent BioSolutions Inc.		•  Prestige Consumer Healthcare Inc.
•  Endo International plc		•  Supernus Pharmaceuticals, Inc.
•  Horizon Therapeutics Public Limited Company		•  Teva Pharmaceutical Industries Limited*
•  Jazz Pharmaceuticals plc		•  United Therapeutics Corporation
•  Lannett Company, Inc.		•  Viatris Inc.*

 

*	New addition in September 2022.

 

At the time of the Compensation Committee’s September 2022 peer group review, Amneal approximated the 65^th, 25^th and 40^th percentiles for revenue, market capitalization and enterprise value, respectively, relative to the 2023 compensation peer group.

 

Components of Executive Compensation

 

Consistent with its pay for performance philosophy, the Compensation Committee believes that it is important to place a greater percentage of executives’ and senior managers’ compensation at risk than that of non-executives and non-senior managers. This is done by tying executives’ and senior managers’ compensation directly to the performance of the Company. Accordingly, as set forth in the charts below, a significant portion of executive compensation consists of annual and long-term incentives linked to the Company’s financial performance and/or the performance of the Company’s stock.

 

Base Salaries

 

The base salary component of our executive compensation program is fixed cash compensation that is based on role, scope of responsibility, experience, previous performance, and competitive pay practices. On an annual basis, the Compensation Committee reviews peer group as well as other compensation survey data as an independent measure to confirm that base salary levels remain reasonable and competitive.

 

The base salaries of our named executive officers as of December 31, 2022 and December 31, 2023, respectively, are reflected in the accompanying table. After two years of no change in the base salaries of the named executive officers, and taking into account factors, including market data regarding base salary changes, the Compensation Committee approved increases to the base salary of each of our named executive officers excluding our Co-CEOs and Mr. Boyer.

 

Name		2022 Base Salary				2023 Base Salary				% Increase				Reason for Change
Chirag Patel		$	750,000			$	750,000				—
Chintu Patel		$	750,000			$	750,000				—
Anastasios Konidaris		$	550,000			$	566,500				3.0	%		Merit
Andrew Boyer		$	600,000			$	600,000				—
Nikita Shah		$	485,000			$	499,550				3.0	%		Merit
Jason Daly		$	435,000			$	478,500				10.0	%		Merit, Market Adjustment

 

Annual and Long-Term Incentive Awards

 

In order to align the interests of our stockholders with our compensation plans, we tie significant portions of our named executive officers’ compensation to our annual and long-term financial, operating and stock price performance through annual cash and long-term equity incentives. The Compensation Committee’s philosophy is that named executive officers should expect the level of their compensation to vary with performance, with compensation increasing when performance exceeds our internal targets and budgets and compensation decreasing when performance falls below these expectations.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		35

Annual Performance-Based Cash Incentive Compensation

 

The Compensation Committee believes that, to reward performance and overall Company success, a portion of an executive officer’s annual cash compensation should be tied to the achievement of the Company’s goals and that individual’s performance goals. The annual incentive program is designed as a pay-for-performance plan and includes components for both Company and individual performance.

 

Company performance is based on achievement of adjusted EBITDA with minimum, target and maximum milestones from which a Company performance multiplier is derived. The minimum performance threshold is 85% of target and the maximum performance level is 125% of target; the associated company performance multiplier ranges from 25% to 150%.

 

Individual performance is also a component of the annual incentive program measured based on achievement of personal/team performance goals and assessment against the Company’s core values. The individual performance multiplier can range from 0-150%. This annual cash incentive payment is calculated as set forth below.

 

Annual Incentive Target Amount	x	Company Performance Multiplier	x	Individual Performance Multiplier	=	Incentive Payment
Targets vary based on level and are expressed as a percentage of base salary		Full year 2023 Company performance is measured based on achievement against adjusted EBITDA goal		Individual performance multiplier can range from 0%-150%

 

The Compensation Committee historically has chosen adjusted EBITDA as the target performance objective for the payment of awards under our annual cash incentive plan. Adjusted EBITDA is not a term defined under U.S. GAAP. We define adjusted EBITDA as net income before net interest expense, income taxes, and depreciation and amortization (“EBITDA”), as adjusted for certain other items described in our SEC filings, including stock-based compensation expense, acquisition, site closure and idle facility expenses, restructuring and other charges, net charges related to legal matters, asset impairment charges, foreign exchange losses or gains, change in fair value of contingent consideration, and insurance recoveries for property losses and associated expenses. Please see “Appendix A – Non-GAAP Measures” for more information, including reconciliations to the most directly comparable GAAP measure.

 

The Compensation Committee believes that adjusted EBITDA growth most closely reflects our operating performance and is a key metric for driving the long-term strategic direction that the Board of Directors has set for our Company. Further, adjusted EBITDA growth is highly correlated to or reflective of our Company’s financial and operational improvements, ability to generate cash flow from operations, growth and long-term return to stockholders. We believe that adjusted EBITDA is helpful in assessing the overall performance of our business and is helpful in highlighting trends in our overall business because the extraordinary or one-time items excluded in calculating adjusted EBITDA have little or no bearing on our day-to-day operating performance. We also believe that adjusted EBITDA is an important non-GAAP valuation tool that potential investors use to measure our profitability against other companies in our industry.

 

Our adjusted EBITDA target for a given year is determined by the Compensation Committee based upon recommendations from and discussions with management, a review of current economic conditions and recent acquisition activity and aligns with our external targets. Factors used by the Compensation Committee in setting adjusted EBITDA targets include, among others, the following:

 

•	reasonable growth expectations taking into account a variety of circumstances faced by our Company;
•	market conditions, including the related impact on cost and our ability to offset any cost increases with pricing increases or other cost savings measures; and
•	prior fiscal year adjusted EBITDA.

 

After the Compensation Committee reviews the final full year financial results of our Company, the Compensation Committee approves annual cash incentive payouts for the prior year. Annual cash incentive awards are generally paid in March.

 

No annual cash incentive payments are made unless the threshold adjusted EBITDA target has been achieved. Adjusted EBITDA targets under the annual cash incentive plan may be reset periodically within a fiscal year by the Compensation Committee to take into account acquisitions, divestitures and other unplanned events. Subject to the provisions of an applicable employment agreement, executives generally must be employed at the time of payout to receive an annual cash incentive award. The Compensation Committee may, however, at its discretion, prorate awards in the event of certain circumstances such as the executive’s promotion, demotion, death or retirement.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		36

The Company performance component of the annual award each executive is eligible to receive is based upon a percentage of the executive’s annualized base salary, with such percentage varying depending upon the level of adjusted EBITDA as compared to threshold, target and maximum adjusted EBITDA performance objectives as set forth in the table below.

 

		Company Performance Component of Annual Bonus Award as a Percentage of Base Salary
Name		Threshold		Target		Maximum
Chirag Patel		25%		100%		150%
Chintu Patel		25%		100%		150%
Anastasios Konidaris		13.75%		55%		82.5%
Andrew Boyer		20%		80%		120%
Nikita Shah		13.75%		55%		82.5%
Jason Daly		12.5%		50%		75%

 

The fiscal 2023 combined adjusted EBITDA threshold, target and maximum performance objectives were $437.75 million, $515 million and $643.75 million, respectively. Our Company’s fiscal 2023 reported adjusted EBITDA was $558 million; furthermore, for purposes of determining performance under the 2023 annual cash incentive plan, the Compensation Committee reviewed and approved, as permitted under the plan, an additional $12 million adjustment to the reported 2023 adjusted EBITDA measure for certain regulatory developments deemed to be outside of management’s control. This resulted in achievement of 110.7% of target and a 121.4% Company performance multiplier.

 

The 2023 annual performance-based cash incentive program also provides for an individual performance multiplier, which ranges from 0% to 150% based on an individual’s performance during the year. In assessing the performance of our NEOs, other than our co-CEOs, the Compensation Committee, with the input of our co-CEOs, considered each officer’s performance against the goals of their respective functions, as well as the executive’s contribution to achievement of our corporate goals. The individual multipliers ranged from 100% to 120%.

 

Name		2023 Base Salary			Annual Incentive Target %		Annual Incentive Target $			X		Company Performance Multiplier %		X		Individual Performance Multiplier %		=		Final AIP Payout $			AIP Payout % of Target
Chirag K. Patel		$	750,000		100%		$	750,000				121.4%				100%				$	910,500		121.4%
Chintu Patel		$	750,000		100%		$	750,000				121.4%				100%				$	910,500		121.4%
Anastasios Konidaris		$	566,500		55%		$	311,575				121.4%				120%				$	453,902		145.7%
Andrew Boyer		$	600,000		80%		$	480,000				121.4%				100%				$	582,720		121.4%
Nikita Shah		$	499,550		55%		$	274,753				121.4%				100%				$	333,550		121.4%
Jason Daly		$	478,500		50%		$	239,250				121.4%				100%				$	290,450		121.4%

 

In determining the individual performance modifier for the named executive officers other than Mr. Konidaris, the Compensation Committee considered that, for 2023, each of the executives met the goals of their respective functions and contributed to the achievement of the Company’s corporate goals. In approving the 120% individual performance modifier for Mr. Konidaris, the Compensation Committee took into consideration, among other things, (1) that Amneal exceeded all of its budgeted financial metrics for 2023, (2) the successful refinancing of a $2.35 billion term loan, the effect of which is to extend the maturity date of an equivalent principal amount of term loans under Amneal’s existing term loan credit agreement to May 4, 2028, and (3) the work performed in support of the Company’s closing of the Reorganization.

 

Long-Term Incentive Compensation

 

Our long-term incentive compensation program is designed to promote a balanced focus on driving performance, retaining talent and aligning the interests of our executives with those of our other stockholders. The Amneal Pharmaceuticals, Inc. Amended and Restated 2018 Incentive Award Plan (the “2018 Incentive Award Plan”) authorizes the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock or cash-based awards and dividend equivalent awards to employees, non-employee directors and consultants.

 

Our long-term incentive compensation program for 2023 for the named executive officers was comprised of two components: performance-based restricted stock units (“PSUs”) and restricted stock units (“RSUs”).

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		37

•	Performance-based restricted stock units. We grant PSUs, which vest upon the attainment of certain performance metrics, in order to further incentivize our executive officers to deliver superior long-term results.
•	Restricted stock units. We grant restricted stock unit awards as a retention tool as they provide the opportunity to receive stock only if the recipient is still employed by us on the date the restrictions lapse.

 

In 2023, the total value of each named executive officer’s equity grants was divided between restricted stock units and PSUs, other than the Co-Chief Executive Officers who received all of their long-term incentive compensation in the form of PSUs. The mix of different types of awards is generally intended to combine the retention and downside risk benefits inherent in restricted stock units with the incentive and stockholder value creation benefits inherent in performance-based restricted stock units.

 

In addition, in order to preserve share capacity under the 2018 Incentive Award Plan, for our 2023 long-term incentive program, the Company utilized the 2022 12-month stock price average in setting the grant price for all equity awards. This 2022 12-month average stock price was $3.27, as compared to an actual date of grant closing price of $1.92. Consequently, grant date fair values for awards under our 2023 long-term incentive plan were only 59% of targeted values. The Company expects to revert back to its historic methodology of using the closing market price of our common stock on the date of grant for setting the grant price with respect to awards under the 2024 long-term incentive plan.

 

Considerations Regarding the Co-Chief Executive Officers’ 2023 Long-Term Incentive Compensation Awards

 

The Compensation Committee forms its recommendation regarding the long-term incentive compensation for the Co-Chief Executive Officers following an in-depth assessment of numerous factors and developments and in consideration of its “pay for performance” philosophy. In making its determinations, the Compensation Committee has historically approached the Co-Chief Executive structure by evaluating the total compensation of the top two executives at peer companies.

 

With respect to the long-term incentive awards made to the Co-Chief Executive Officers in 2023, the Compensation Committee initially targeted a total long-term incentive compensation package for each of the Co-Chief Executive Officers of $2.4 million solely in the form of PSUs, representing a below-market value lower than the 25^th percentile of the Company’s peer group companies. Given the economic headwinds impacting the Company’s share price development, for fiscal year 2023, the Co-Chief Executive Officers proposed, and the Compensation Committee agreed, that the Co-Chief Executive Officers would be awarded half of the targeted long-term incentive award, or $1.2 million, an amount that resulted in total annual compensation significantly below the Company’s peer group median. This proactive proposal to reduce the value of the Co-Chief Executive Officers’ long-term incentive award for 2023 was further affected by the Company’s decision to use the 12-month average stock price for FY 2022 ($3.27) in setting the grant price for 2023 long-term incentive awards. This award pricing methodology, coupled with the use of a Monte Carlo valuation, further reduced the fair market value of the Co-Chief Executive Officers’ long-term incentive awards to approximately $664,000 each, as reflected in the Summary Compensation Table.

 

The following table sets forth the total grant value and components mix determined for issuance to our named executive officers in 2023:

 

Name		Value of 2023 Awards(1)				% PSUs		% RSUs
Chirag Patel		$	1,200,000			100%
Chintu Patel		$	1,200,000			100%
Anastasios Konidaris		$	1,500,000			50%		50%
Andrew Boyer		$	1,300,000			50%		50%
Nikita Shah		$	1,200,000			50%		50%
Jason Daly		$	1,000,000			50%		50%

 

(1)	Values in the table represent the determined grant value. Actual awards were based on this value using the 2022 twelve-month average closing stock price, which was $3.27.

 

Restricted Stock Unit Awards

 

In 2023, annual restricted stock unit grants were made in March for all of the named executive officers, other than our Co-Chief Executive Officers, who received no restricted stock unit grants. All of the restricted stock unit awards vest in four equal installments on the first, second, third and fourth anniversary of the grant date subject to cancellation or acceleration as provided in the individual restricted stock unit award agreements. The number of restricted stock unit awards granted to each named executive officer in 2023 was based upon the 2022 twelve-month average closing stock price. For additional details on this award, see “Executive Compensation—Management Employment & Separation Agreements” below.

 

Performance-Based Restricted Stock Unit Awards

 

In 2023, our named executive officers were granted PSU awards in March. These awards will be earned at a rate of 0% and 200% of the target award amounts based on the Company’s achievement of a stock price growth target relative to the 30-day average closing stock price preceding the grant date, which was $2.34, during the performance period from March 1, 2023 until February 28, 2026. A payout of 75% of the target award is earned at the achievement of 150% of the stock price growth target based on the trailing average closing stock price of our common stock over the 60 calendar days preceding February 28, 2026, and a payout of 200% of the target award if the average closing stock price is 300% or greater of the stock price growth target. Any earned awards vest in full at the end of such performance period, subject to cancellation or acceleration as provided in the individual performance-based restricted stock unit award agreements. The number of PSUs granted to each named executive officer is based upon the 2022 twelve-month average closing stock price.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		38

Performance-Based Restricted Stock Unit Award Determinations for 2023

 

In 2021, Messrs. Chirag Patel, Chintu Patel, Boyer and Konidaris and Ms. Shah were granted Performance-Based Restricted Stock that would vest based on achievement of an absolute stock price target. Actual performance during the three-year performance period of March 1, 2021 through February 28, 2024 was below the absolute stock price threshold of $8.00, resulting in no payout. As a result, the underlying awards were cancelled.

 

Other Compensation and Benefits

 

Benefits offered to our named executive officers serve a different purpose than do the other elements of total compensation. In general, they are provided for the convenience of the Company or are designed to provide a safety net of protection against the financial catastrophes that can result from illness, disability or death. Most benefits offered to our named executive officers are generally the same as those offered to the general employee population.

 

Under the Company’s 401(k) plan, the Company makes a 100% matching contribution with respect to each participant’s elective contributions, up to 5% percent of such participant’s compensation (provided that for fiscal 2022, matching contributions were based only on the first $305,000 of such participant’s compensation in accordance with Internal Revenue Code limitations). Matching contributions generally become fully vested after three years of employment with the Company.

 

Executive Severance and Change in Control Severance Benefits

 

For a discussion of executive severance and change in control severance benefits, our rationale for offering those benefits and the triggers for payments, see “Management Employment & Separation Agreements—Severance Upon a Change in Control” below.

 

Consideration of 2023 Say-on-Pay Vote

 

At the 2023 Annual Meeting of Stockholders, our “say-on-pay” advisory vote received 98.4% support. The Compensation Committee regarded this vote, as well as feedback from our engagement with stockholders, as demonstrating strong support for our executive compensation program and did not make any significant changes to our compensation programs as a result of this vote.

 

Accounting and Tax Considerations

 

Financial reporting and income tax consequences to our Company of individual compensation elements are important considerations for our Compensation Committee when it is analyzing the overall level of compensation and the mix of compensation. Overall, the Compensation Committee seeks to balance its objective of maintaining a fair, reasonable and competitive compensation package for our named executive officers with enabling the deductibility of compensation.

 

Executive Compensation Clawback Policy

 

Effective October 2, 2023, the Compensation Committee adopted our Clawback Policy to comply with applicable listing standards, which implements the final rule promulgated by the SEC for recovery of erroneously awarded compensation. The Clawback Policy requires recovery of any excess incentive-based compensation from any current or former executive officers subject to Section 16 of the Exchange Act (“Section 16”) following a restatement of financial information that affects a financial measure used to determine such incentive-based compensation.

 

The excess amount is any such amount by which the affected incentive-based compensation exceeds the compensation that would have been received by the executive officer, without regard to any taxes paid, had the applicable financial measure not been subject to error. Under the Clawback Policy, our Compensation Committee determines the method of recovery, and recovery may be deemed impractical only in limited circumstances enumerated in the Nasdaq listing standards.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		39

Stock Ownership Guidelines for Executive Officers

 

In order to further align the interests of our management with the interests of our stockholders, we require our executive officers to own shares of our stock as set forth below.

 

Position	Minimum Ownership Guideline
Co-Chief Executive Officers	6x base salary
Other Executive Officers	2x base salary

 

We adopted our stock ownership guidelines in May 2018, and we expect our executive officers to be able to achieve the required ownership thresholds by five years from the date of adoption of the guidelines. Newly appointed officers will have five years from the date they became subject to the stock ownership guidelines to comply with them. For the purpose of determining stock ownership levels, we include shares owned directly or by immediate family members residing in the same household (or through trusts for their benefit) and underlying restricted stock and restricted stock units (whether or not vested), but exclude shares underlying unexercised stock option awards and unearned performance awards. All of our named executive officers are in compliance with these requirements.

 

See “Corporate Governance—Director Compensation—Director Stock Ownership Guidelines” above for a description of stock ownership guidelines we have adopted for our non-employee directors.

 

Anti-Hedging Policy

 

To prevent speculation or hedging, our insider trading policy prohibits our named executive officers (and our directors and all other employees) from engaging in short sales of our Company’s stock. Company policy also prohibits our directors, executive officers and certain other employees from purchasing or selling any financial instrument that is designed to hedge or offset any decrease in the market value of our Company’s stock, including prepaid variable forward contracts, equity swaps, collars and other derivative securities that are directly linked to our Company’s stock. All other employees are discouraged, but not expressly prohibited, from entering into hedging transactions related to Company stock. In addition, pursuant to our Corporate Governance Guidelines, directors and executive officers who are not Amneal Group Members (as defined in the Stockholders Agreement) are prohibited from pledging Company stock as collateral for a loan.

 

Report of the Compensation Committee

 

The Compensation Committee of the Board of Directors has reviewed and discussed the foregoing Compensation Discussion and Analysis with management. Based on this review and discussion, the committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and incorporated by reference into the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. This report is provided by the following directors, who comprise the committee.

 

Compensation Committee:

 

Ted Nark (Chair)
Jeff George
Paul Meister
Shlomo Yanai

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		40

Summary Compensation Table

 

The following table shows the compensation of our named executive officers for the periods presented. The sum and/or computation of individual numerical amounts disclosed in the following table and related footnotes may not equal the total due to rounding.

 

Name and Principal Position		Year		Salary ($)		Bonus ($)		Stock Awards(1) ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		All Other Compensation(2) ($)		Total ($)
Chirag Patel		2023		750,000		—		664,219		—		910,500		45,666		2,370,386
Co-Chief Executive Officer and President		2022		750,000		—		3,605,796		—		652,500		39,814		5,048,110
		2021		724,038		—		3,266,406		—		757,500		37,172		4,785,116
Chintu Patel		2023		750,000		—		664,219		—		910,500		42,833		2,367,553
Co-Chief Executive Officer		2022		750,000		—		3,605,796		—		652,500		54,436		5,062,732
		2021		724,038		—		3,266,406		—		757,500		50,881		4,798,825
Anastasios Konidaris		2023		563,327		—		855,505		—		453,902		18,531		1,891,266
EVP & Chief Financial Officer		2022		550,000		—		1,876,807		—		289,493		16,886		2,733,186
		2021		550,000		—		1,770,757		—		326,912		16,327		2,663,996
Andrew Boyer		2023		600,000		—		741,438		—		582,720		18,531		1,942,689
EVP, Chief Commercial Officer - Generics		2022		600,000		—		1,626,572		—		438,480		16,886		2,681,937
		2021		600,000		—		1,534,657		—		484,800		16,406		2,635,863
Nikita Shah		2023		496,752		—		684,403		—		333,550		18,528		1,533,232
EVP, Chief Human Resources Officer		2022		485,000		—		1,501,454		—		255,519		16,886		2,258,859
		2021		483,789		—		1,416,601		—		307,136		16,169		2,223,694
Jason Daly		2023		470,135		—		570,336		—		290,450		18,476		1,349,396
Senior Vice President, Chief Legal Officer & Secretary		2022		401,538		175,000		938,409		—		189,225		16,765		1,720,937

(1)

These amounts reflect the aggregate grant date fair value of each restricted stock unit award and PSU award granted during the fiscal year, computed in accordance with FASB ASC Topic 718. The valuation assumptions used in determining such amounts are described in Note 23 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. For the PSU awards granted in 2023, the value of the awards as of the grant date, assuming that the highest level of performance achievement would be achieved (which is 200% of target), for Mr. Chirag Patel, Mr. Chintu Patel, Mr. Konidaris, Mr. Boyer, Ms. Shah and Mr. Daly would be $1,328,439, $1,328,439, $830,276, $719,573, $664,219 and $553,516, respectively.

(2)

The amounts shown in this column for 2023 consist of the following components:

 

	Name		Company 401(k) Match ($)		Life and Disability Insurance Premiums Paid by Company ($)		Cost for Personal Use of Driver and Company Car(1) ($)		Total ($)
	Chirag Patel		16,500		2,031		27,135		45,666
	Chintu Patel		16,500		2,031		24,302		42,833
	Anastasios Konidaris		16,500		2,031		—		18,531
	Andrew Boyer		16,500		2,031		—		18,531
	Nikita Shah		16,500		2,028		—		18,528
	Jason Daly		16,500		1,976		—		18,476

(1)

We own a car and employ a driver for the exclusive use of each of Mr. Chirag Patel and Mr. Chintu Patel. Although the majority of the driver’s services (and, therefore, the costs associated with the car) are for business purposes, we allow for use of the car and driver for personal purposes - generally for daily commute - as we believe this accommodation enables increased productivity during this time. We calculated the incremental cost to us for the personal use of the Company car and driver based on the costs associated with the car, its operation, and a portion of the driver’s compensation equivalent in proportion to the time the car is used for personal purposes.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		41

Grants of Plan Based Awards in 2023

 

The following tables set forth information about non-equity and equity awards granted to the named executive officers in fiscal 2023.

 

				Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1)						Estimated Future Payouts Under Equity Incentive Plan Awards(2)						All Other Stock Awards: Number of Shares of		Grant Date Fair Value of Stock and
Name		Grant Date		Threshold ($)		Target ($)		Maximum ($)		Threshold (#)		Target (#)		Maximum (#)		Stock or Units(3) (#)		Option Awards(4) ($)
Chirag Patel
2023 Annual Cash Incentive				187,500		750,000		1,125,000
PSU Grant		3/3/23								183,486		366,972		733,944				664,219
Chintu Patel
2023 Annual Cash Incentive				187,500		750,000		1,125,000
PSU Grant		3/3/23								183,486		366,972		733,944				664,219
Anastasios Konidaris
2022 Annual Cash Incentive				77,894		311,575		467,363
PSU Grant		3/3/23								114,679		229,358		458,716				415,138
RSU Grant		3/3/23														229,358		440,367
Andrew Boyer
2023 Annual Cash Incentive				120,000		480,000		720,000
PSU Grant		3/3/23								99,389		198,777		397,554				359,786
RSU Grant		3/3/23														198,777		381,652
Nikita Shah
2023 Annual Cash Incentive				68,688		274,753		412,129
PSU Grant		3/3/23								91,743		183,486		366,972				332,110
RSU Grant		3/3/23														183,486		352,293
Jason Daly
2023 Annual Cash Incentive				59,813		239,250		358,875
PSU Grant		3/3/23								76,453		152,905		305,810				276,758
RSU Grant		3/3/23														152,905		293,578

(1)	The amounts shown in these columns reflect the corporate performance targets under our annual performance-based cash incentive plan. “Threshold” equals 25% of Target, “Target” equals 100% and “Maximum” equals 150% of Target.
(2)	The number of shares shown reflects the “Threshold,” “Target” and “Maximum” payout levels under the 2023 performance-based restricted stock unit awards granted under the 2018 Incentive Award Plan. “Threshold” equals 50% of Target, “Target” equals 100% of Target and “Maximum” equals 200% of Target.
(3)	The number of shares shown reflects the 2023 restricted stock unit awards under the 2018 Incentive Award Plan. The restricted stock unit awards made in 2023 vest in four equal installments on the first, second, third and fourth anniversary of the date of grant, assuming continued employment.
(4)	These amounts reflect the aggregate grant date fair value of each stock award granted during the fiscal year, computed in accordance with FASB ASC Topic 718. The valuation assumptions used in determining such amounts are described in Note 23 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. As the PSUs were subject to market-based vesting conditions, the grant date fair value was determined using a Monte-Carlo simulation model, which is a probabilistic approach for estimating the grant date fair value of the PSUs for purposes of accounting under FASB ASC Topic 718.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		42

Outstanding Equity Awards at December 31, 2023

 

		Option Awards										Stock Awards
Name		Number of Securities Underlying Options that are Exercisable (#)		Number of Securities Underlying Options that are Unexercisable (#)		Option Exercise Price ($)		Option Expiration Date		Number of Shares or Units of Stock that Have Not Vested (#)		Market Value of Shares or Units of Stock that Have Not Vested(1) ($)		Equity Incentive Plan Awards: Number of Unearned Shares, Units, or Other Rights that Have Not Vested (#)		Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units, or Other Rights that Have Not Vested ($)
Chirag Patel		24,977		—		15.01		5/7/28
		28,044		—		14.05		5/6/29
														0(7)		—
														289,855(8)		1,759,420
														733,944(9)		4,455,040
Chintu Patel		24,977		—		15.01		5/7/28
		28,044		—		14.05		5/6/29
														0(7)		—
														289,855(8)		1,759,420
														733,944(9)		4,455,040
Anastasios										87,720(2)		532,460
Konidaris										72,394(3)		439,432		0(7)		—
										135,870(4)		824,731		90,580(8)		549,821
										229,358(5)		1,392,203		458,716(9)		2,784,406
Andrew Boyer		272,480		—		2.75		5/7/28
		100,553		—		2.75		3/1/29
										31,663(6)		192,194
										62,742(3)		380,844		0(7)		—
										117,754(4)		714,767		78,503(8)		476,513
										198,777(5)		1,206,576		397,554(9)		2,413,153
Nikita Shah		36,331		—		2.75		5/7/28
		95,525		23,882	(2)	2.75		3/1/29
										35,620(6)		216,213
										57,915(3)		351,544		0(7)		—
										108,696(4)		659,785		72,464(8)		439,856
										183,486(5)		1,113,760		366,972(9)		2,227,520
Jason Daly										67,935(4)		412,365		45,290(8)		274,910
										152,905(5)		928,133		305,810(9)		1,856,267

(1)	Based on the closing price of our Class A common stock of $6.07 on December 29, 2023, the last trading day of the year.
(2)	Restricted stock units vest in one installment on March 12, 2024.
(3)	Restricted stock units vest in two equal installments on March 1, 2024 and March 1, 2025.
(4)	Restricted stock units vest in three equal installments on March 3, 2024, March, 3, 2025, and March 3, 2026.
(5)	Restricted stock units vest in four equal installments on March 3, 2024, March 3, 2025, March, 3, 2026, and March 3, 2027.
(6)	Restricted stock units vest in one installment on February 27, 2024.
(7)	The performance-based restricted stock units vest following the conclusion of the March 1, 2021 through February 29, 2024 performance period based upon the level of attainment of absolute stock price (based on the closing stock price of the Company’s stock on NASDAQ). Payouts for this performance period are estimated at 0% of the target level.
(8)	The performance-based restricted stock units vest following the conclusion of the March 1, 2022 through February 28, 2025 performance period based upon the level of attainment of stock price growth (based on the closing stock price of the Company’s stock on NASDAQ). The amounts listed represent the threshold number of units under each award. Total shares earned under the performance-based restricted stock units will range from 0% to 200% of the target number of units based on actual performance.
(9)	The performance-based restricted stock units vest following the conclusion of the March 1, 2023 through February 28, 2026 performance period based upon the level of attainment of stock price growth (based on the closing stock price of the Company’s stock on NASDAQ). The amounts listed represent the maximum number of units under each award as the estimated payout as of the end of 2023 is above target level performance. Total shares earned under the performance-based restricted stock units will range from 0% to 200% of the target number of units based on actual performance.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		43

2023 Option Exercises and Stock Vested

 

		Option Awards				Stock Awards
Name		Number of Shares Acquired on Exercise (#)		Value Realized on Exercise ($)		Number of Shares Acquired on Vesting (#)		Value Realized on Vesting(1) ($)
Chirag Patel		—		—		—		—
Chintu Patel		—		—		—		—
Anastasios Konidaris		—		—		169,205		296,817
Andrew Boyer		—		—		137,725		306,715
Nikita Shah		—		—		112,539		231,540
Jason Daly		—		—		22,645		43,478

(1)	Amounts reported are based on the closing price of our Class A common stock on the New York Stock Exchange on the vesting date.

 

Management Employment & Separation Agreements

 

Among our named executive officers, we have or had employment agreements with Andrew Boyer, Anastasios Konidaris and Nikita Shah.

 

Andrew Boyer

 

Andrew Boyer is party to an Employment Agreement, effective as of February 5, 2018, with Amneal (the “Boyer Employment Agreement”).

 

The initial term of the Boyer Employment Agreement began on February 5, 2018 and was scheduled to expire on June 30, 2022, unless further extended or earlier terminated as provided in the Boyer Employment Agreement.

 

On July 31, 2020, the Company entered into Modification No. 1 to the Boyer Employment Agreement, effective as of August 1, 2020 (the “Effective Date”). Pursuant to the Modification, the term of Mr. Boyer’s Employment Agreement was extended until June 30, 2023 (the “Term”) and will automatically be renewed thereafter for single one-year periods unless written notice of non-renewal is provided by any party at least 90 days prior to the end of the Term or the agreement is earlier terminated in accordance with its terms. Under the Modification, as of the Effective Date, Mr. Boyer began serving as the Executive Vice President, Chief Commercial Officer – Generics and receiving an annual base salary of $600,000 (reduced from $661,917), which amount is subject to increase by the Company’s Board of Directors. Further, in connection with the Modification, Mr. Boyer received an award of restricted stock units having a grant date fair value equal to $300,000 with a third of such units vesting on each of June 30, 2021, June 30, 2022 and June 30, 2023, subject to Mr. Boyer’s continued employment through the applicable vesting date.

 

On February 21, 2023, the Company entered into Modification No. 2 to the Boyer Employment Agreement, effective as of March 1, 2023 (the “Effective Date”). Pursuant to the Modification, the term of Mr. Boyer’s Employment Agreement was extended until March 31, 2025 (the “Term”) and will automatically be renewed thereafter for single one-year periods unless written notice of non-renewal is provided by any party at least 90 days prior to the end of the Term or the agreement is earlier terminated in accordance with its terms. As described in further detail under “Certain Related Parties and Related Party Transactions – The Reorganization,” we entered into an administrative amendment to the Boyer Employment Agreement in light of the Reorganization, namely to clarify that (i) Mr. Boyer will remain directly employed by Amneal LLC, and (ii) all references in such employment agreement to Old Amneal (as defined herein) shall be deemed to instead refer to New Amneal.

 

Mr. Boyer is also eligible to receive an annual bonus targeted at 80% of his base salary under the annual bonus program, and a personal performance multiplier based on his performance and as determined by the Board in its discretion of between zero and 150% of this amount.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		44

Severance

 

The Boyer Employment Agreement provides for severance payments and benefits if (i) Mr. Boyer resigns for “good reason” (as defined in the Boyer Employment Agreement) or (ii) the Board of Directors terminates Mr. Boyer’s employment without “cause” (as defined in the Boyer Employment Agreement), in each case other than during the period that is within three months preceding or 24 months following a “change in control” (as defined in the Boyer Employment Agreement). In addition to payment of earned and vested payments and benefits, these severance payments and benefits include: (A) two times his base salary as then in effect; (B) a pro rata portion of his annual bonus for the fiscal year in which the termination occurs, based on actual performance for such fiscal year, and the prior year’s bonus to the extent not then already paid (based on the higher of target or actual performance of the relevant goals); (C) continuation of healthcare benefits until the second anniversary of his termination date; (D) the vesting and, if applicable, exercisability of each outstanding equity award granted to Mr. Boyer will be accelerated to the extent such equity award would have vested had Mr. Boyer’s employment continued until the first anniversary of his termination date (and, to the extent applicable, each outstanding equity award granted to Mr. Boyer will remain exercisable until the first anniversary of his termination date); and (E) outplacement services by a reputable national outplacement service for up to two years following his termination date.

 

Severance Upon a Change in Control

 

The Boyer Employment Agreement also provides for severance payments and benefits if (i) Mr. Boyer resigns for good reason, (ii) the Board of Directors terminates Mr. Boyer’s employment without cause or (iii) Mr. Boyer’s employment terminates by reason of death or disability (as defined in the Boyer Employment Agreement), in each case within three months preceding or 24 months following a change in control. In addition to payment of earned and vested payments and benefits, these severance payments and benefits include: (A) the sum of (x) two times his base salary as then in effect plus (y) two times his target annual bonus as then in effect; (B) a pro rata portion of his annual bonus for the fiscal year in which the termination occurs, based on actual performance for such fiscal year, and the prior year’s bonus to the extent not then already paid (based on the higher of target or actual performance of the relevant goals); (C) continuation of healthcare benefits until the second anniversary of his termination date; (D) the vesting and, if applicable, exercisability of each equity award granted to Mr. Boyer will be fully accelerated (and, to the extent applicable, each outstanding equity award granted to Mr. Boyer will remain exercisable until the first anniversary of his termination date); and (E) outplacement services by a reputable national outplacement service for up to two years following his termination date.

 

The Boyer Employment Agreement requires Mr. Boyer to maintain the confidentiality of information relating to the Company during and after the term of such agreement and also contains non-competition, non-solicitation and non-disparagement covenants as well as other provisions customary for this type of employment agreement.

 

Anastasios Konidaris

 

Anastasios Konidaris is party to an Employment Agreement, dated March 11, 2020, by and among Amneal, the Company and Mr. Konidaris (the “Konidaris Employment Agreement”).

 

The Konidaris Employment Agreement provides that Mr. Konidaris will be employed as the Company’s Executive Vice President and Chief Financial Officer at an annual base salary of $550,000. Further, Mr. Konidaris is eligible to earn annual incentive compensation under the Company’s annual bonus plan, with the target amount of his annual bonus being equal to 55% of his base salary and a personal performance multiplier based on his performance and as determined by the Board in its discretion of between zero and 150% of this amount. Pursuant to the Konidaris Employment Agreement, not later than 30 days following the effective date of the agreement, the Company granted to Mr. Konidaris an award of restricted stock units having a value equal to $1,000,000 and an award of PSUs having a value equal to $1,000,000. Subject to Mr. Konidaris’s continuous services to the Company through each vesting date, the restricted stock units will vest in four equal installments beginning on the first anniversary of the effective date of the Konidaris Employment Agreement, and the PSUs will be earned and will vest based on the same vesting and performance conditions as the performance-based restricted stock units awarded to the Company’s other named executive officers in 2020.

 

On February 21, 2023, the Company entered into Modification No. 2 to the Konidaris Employment Agreement, effective as of March 1, 2023 (the “Effective Date”). Pursuant to the Modification, the term of Mr. Konidaris’ Employment Agreement was extended until March 31, 2025 (the “Term”) and will automatically be renewed thereafter for single one-year periods unless written notice of non-renewal is provided by any party at least 90 days prior to the end of the Term or the agreement is earlier terminated in accordance with its terms. As described in further detail under “Certain Related Parties and Related Party Transactions—The Reorganization,” we entered into an administrative amendment to the Konidaris Employment Agreement in light of the Reorganization, namely to clarify that (i) Mr. Konidaris will be directly employed by Amneal LLC rather than Old Amneal, and (ii) all references in such employment agreement to Old Amneal shall be deemed to instead refer to New Amneal (other than references relating to Old Amneal as employer which shall be deemed to instead refer to Amneal LLC as employer as of the effective time of the Reorganization).

 

Severance

 

In the case of termination by the Company without cause or a termination by Mr. Konidaris for good reason (each as defined in the Konidaris Employment Agreement), Mr. Konidaris will be entitled to receive the following severance benefits: (1) an amount equal to 150% of his then-current annual base salary; (2) a prorated portion of the annual bonus award for the year during which the termination occurs, based on actual performance for such fiscal year; (3) benefits continuation for a period of 18 months following the date of termination; and (4) outplacement assistance for a period of 12 months following the date of termination.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		45

Severance Upon a Change in Control

 

In the case of a termination by the Company without cause or a termination by Mr. Konidaris for good reason within three months prior to or 12 months following a change in control (as defined in the Konidaris Employment Agreement), Mr. Konidaris will be entitled to receive the severance benefits described above. In addition, the vesting and exercisability of each equity award granted to Mr. Konidaris will accelerate effective as of the date of termination, with any performance conditions determined based on actual achievement as of the date of termination, and, if applicable, will remain exercisable for a period of not less than 12 months following the termination.

 

Nikita Shah

 

Nikita Shah is party to an Employment Agreement, dated July 29, 2020, by and among Amneal, the Company and Ms. Shah (the “Shah Employment Agreement”).

 

The Shah Employment Agreement provides that Ms. Shah will be employed as the Company’s Executive Vice President, Chief Human Resources Officer at an annual base salary of (i) $450,000 beginning on August 1, 2020; and (ii) $485,000 beginning on January 1, 2021. Further, Ms. Shah is eligible to earn annual incentive compensation under the Company’s annual bonus plan with the target amount of her annual bonus being equal to 55% of her base salary and a personal performance multiplier based on her performance and as determined by the Board in its discretion of between zero and 150% of this amount. Ms. Shah will be eligible to participate in the Company’s long term incentive plan.

 

On February 21, 2023, the Company entered into Modification No. 1 to the Shah Employment Agreement, effective as of March 1, 2023 (the “Effective Date”). Pursuant to the Modification, the term of Ms. Shah’s Employment Agreement was extended until March 31, 2025 (the “Term”) and will automatically be renewed thereafter for single one-year periods unless written notice of non-renewal is provided by any party at least 90 days prior to the end of the Term or the agreement is earlier terminated in accordance with its terms. As described in further detail under “Certain Related Parties and Related Party Transactions—The Reorganization,” we entered into an administrative amendment to the Shah Employment Agreement in light of the Reorganization, namely to clarify that (i) Ms. Shah will be directly employed by Amneal LLC rather than Old Amneal, and (ii) all references in such employment agreement to Old Amneal shall be deemed to instead refer to New Amneal (other than references relating to Old Amneal as employer which shall be deemed to instead refer to Amneal LLC as employer as of the effective time of the Reorganization.

 

Severance

 

In the case of termination by the Company without cause or a termination by Ms. Shah for good reason (each as defined in the Shah Employment Agreement), Ms. Shah will be entitled to receive the following severance benefits: (1) an amount equal to 150% of her then-current annual base salary; (2) a pro-rated portion of the annual bonus award for the year during which the termination occurs, based on actual performance for such fiscal year; (3) benefits continuation for a period of 18 months following the date of termination; (4) the vesting and, if applicable, exercisability of each outstanding equity award granted to Ms. Shah will be accelerated to the extent such equity award would have vested had Ms. Shah’s employment continued until the first anniversary of her termination date (and, to the extent applicable, each outstanding equity award granted to Ms. Shah will remain exercisable until the first anniversary of her termination date); and (5) outplacement assistance for a period of 12 months following the date of termination.

 

Severance Upon a Change in Control

 

In June 2020, the Compensation Committee approved severance benefits for Ms. Shah in the case of a termination by the Company without cause or a termination by Ms. Shah for good reason within three months prior to or 12 months following a change in control (as defined in the Shah Employment Agreement); in such case, Ms. Shah will be entitled to receive the severance benefits described above. In addition, the vesting and exercisability of each outstanding equity award granted to Ms. Shah will accelerate effective as of the date of termination, with any performance conditions determined based on actual achievement as of the date of termination, and, if applicable, will remain exercisable for a period of not less than 12 months following the termination.

 

Severance Plan

 

On June 17, 2020, the Compensation Committee adopted the Amneal Pharmaceuticals LLC Severance Plan (the “Severance Plan”). The Severance Plan is intended to constitute an “employee welfare benefit plan” under Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Under the Severance Plan, in the event of (a) a participant’s involuntary termination of employment without Cause (as defined below) due to (i) a reduction-in-force; (ii) a layoff; (iii) the elimination of a participant’s role; (iv) the reorganization of the Company, or a business unit, division, or department of the Company; (v) a change in business plan or structure that results in the participant’s separation from employment; or (vi) any other reason as determined by the Company in its sole discretion or (b) a mandatory relocation of a participant’s primary workplace to a location that is more than fifty (50) miles from a participant’s prior primary workplace, on an individualized basis the participant will be eligible to receive up to a maximum of (depending on his or her position) (A) a lump sum payment of 52 weeks of his or her base

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		46

pay, (B) a prorated portion of his or her incentive award, (C) fully subsidized COBRA premiums for 52 weeks, and (D) outplacement services for 52 weeks. Under the Severance Plan, in the event of a participant’s termination in connection with a change of control, the participant will be eligible to receive up to a maximum of (depending on his or her position) (A) a lump sum payment of 64 weeks of his or her base pay, (B) prorated target bonus, (C) fully subsidized COBRA premiums up to a maximum of 64 weeks, and (D) outplacement services up to a maximum for 64 weeks.

 

Executive officers who are subject to an individual employment agreement or contract with the Company or any member of the Company Group are excluded from participation in Severance Plan. Mr. Daly is not subject to an individual employment agreement or contract with the Company, and as such, Mr. Daly participates in the Severance Plan.

 

As used in the Severance Plan, “Cause” means (i) any failure or neglect by the participant to perform his or her duties or responsibilities to the Company or any of its subsidiaries (the “Company Group”), (ii) any act of fraud, embezzlement, theft, misappropriation, or material dishonesty by the participant relating to the Company Group or its business or assets, (iii) the participant’s commission of a felony or other crime involving moral turpitude, (iv) any gross negligence or intentional misconduct on the part of the participant in the conduct of his or her duties and responsibilities or services, as applicable, with the Company Group or its affiliates or that adversely affects the image, reputation or business of the Company Group or its affiliates, or (v) any material breach by the participant of any written agreement between the Company Group and the participant or any written policy applicable generally to employees of the Company Group.

 

Potential Payments Upon Termination or Change in Control

 

To enable us to offer a competitive executive compensation program, we believe it is important to provide reasonable severance benefits to our executive officers.

 

In addition to the employment agreements between the Company and certain of our named executive officers and the Severance Plan, discussed above, from time to time, we may explore potential transactions that could result in a change in control of our Company. We believe that when a transaction is perceived as imminent, or is taking place, we should be able to receive and rely on the disinterested service of our executive officers, without them being distracted or concerned by the personal uncertainties and risks associated with such a situation. We further believe that our stockholders are best served if their interests are aligned with the interests of our executives, and providing change in control benefits should eliminate, or at least reduce, the reluctance of senior management to pursue potential transactions that may enhance the value of our stockholders’ investments. Consistent with this, we provide change-in-control benefits to our named executive officers only if the officer’s employment terminates in connection with the change in control (often referred to as “double-trigger” change-in-control benefits).

 

The estimated severance and other benefits for each named executive officer, either pursuant to the Severance Plan or an applicable employment agreement, in the event of a termination of employment are set forth below. The amounts assume that the termination was effective as of December 29, 2023 (the last business day of fiscal 2023) and thus are based upon amounts earned through such date and are only estimates of the amounts that would actually be paid to such named executive officers upon their termination. Since many factors (e.g., the time of year when the event occurs, the Company’s stock price) could affect the nature and amount of benefits a named executive officer could potentially receive, any amounts paid or distributed upon a future termination may be different from those shown in the table below. The amounts shown are in addition to benefits generally available to salaried employees. Mr. Chirag Patel and Mr. Chintu Patel do not participate in the Severance Plan nor do they have an applicable employment agreement with severance terms in the event of a termination of employment.

 

Under our performance-based restricted stock unit agreements, upon an NEO’s “Qualifying Termination” prior to the end of the applicable performance period, the number of performance-based restricted stock units earned by the employee would be determined as of the employee’s termination date based on actual performance through such date. For purposes of this paragraph, a “Qualifying Termination” shall mean such employee’s termination of service prior to the end of the applicable performance period due to death, permanent disability or involuntary termination by the Company without “cause.” In the event of a Change in Control prior to the end of the three-year performance period, the number of performance-based restricted stock units earned will be determined as of the date of the Change in Control based on actual performance through such date. Such performance-based restricted stock units that are deemed earned pursuant to the preceding sentence will vest on the date of the Change in Control, subject to the employee’s continued employment or service to the Company or its subsidiaries through the date of the Change in Control.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		47

			Without Cause or for Good Reason Termination
Name		Benefit		Without Change in Control				With Change in Control				Termination for Death				Termination for Disability
Chirag Patel		Cash		$	—			$	—			$	—			$	—
		Accelerated options		$	—			$	—			$	—			$	—
		Accelerated RSUs(1)		$	—			$	—			$	—			$	—
		PSUs(2)		$	2,784,400			$	2,784,400			$	2,784,400			$	2,784,400
		Health Care & Outplacement		$	—			$	—			$	—			$	—
		TOTAL		$	2,784,400			$	2,784,400			$	2,784,400			$	2,784,400
Chintu Patel		Cash		$	—			$	—			$	—			$	—
		Accelerated options		$	—			$	—			$	—			$	—
		Accelerated RSUs(1)		$	—			$	—			$	—			$	—
		PSUs(2)		$	2,784,400			$	2,784,400			$	2,784,400			$	2,784,400
		Health Care & Outplacement		$	—			$	—			$	—			$	—
		TOTAL		$	2,784,400			$	2,784,400			$	2,784,400			$	2,784,400
Anastasios Konidaris		Cash		$	1,303,652			$	1,303,652			$	—			$	—
		Accelerated options		$	—			$	—			$	—			$	—
		Accelerated RSUs(1)		$	—			$	3,188,826			$	—			$	—
		PSUs(2)		$	1,740,254			$	1,740,254			$	1,740,254			$	1,740,254
		Health Care & Outplacement		$	58,413			$	58,413			$	—			$	—
		TOTAL		$	3,102,319			$	6,291,145			$	1,740,254			$	1,740,254
Andrew Boyer		Cash		$	1,782,720			$	2,742,720			$	—			$	—
		Accelerated options		$	—			$	—			$	—			$	—
		Accelerated RSUs(1)		$	922,516			$	2,494,382			$	—			$	—
		PSUs(2)		$	1,508,220			$	1,508,220			$	1,508,220			$	1,508,220
		Health Care & Outplacement		$	122,203			$	122,203			$	—			$	—
		TOTAL		$	4,335,660			$	6,857,525			$	1,508,220			$	1,508,220
Nikita Shah		Cash		$	1,082,875			$	1,082,875			$	—			$	—
		Accelerated options		$	—			$	—			$	—			$	—
		Accelerated RSUs(1)		$	657,785			$	2,341,302			$	—			$	—
		PSUs(2)		$	1,392,200			$	1,392,200			$	1,392,200			$	1,392,200
		Health Care & Outplacement		$	58,413			$	58,413			$	—			$	—
		TOTAL		$	3,191,273			$	4,874,790			$	1,392,200			$	1,392,200
Jason Daly		Cash		$	768,950			$	879,373			$	—			$	—
		Accelerated options		$	—			$	—			$	—			$	—
		Accelerated RSUs(1)		$	—			$	1,340,499			$	—			$	—
		PSUs(2)		$	1,160,167			$	1,160,167			$	1,160,167			$	1,160,167
		Health Care & Outplacement		$	61,105			$	72,206			$	—			$	—
		TOTAL		$	1,990,221			$	3,452,244			$	1,160,167			$	1,160,167

 

(1)	Represents unvested restricted stock units that would accelerate in connection with the applicable termination event valued based on the closing price of our Class A common stock on December 29, 2023, which was $6.07.
(2)	Represents unvested performance-based restricted stock units that would be earned in connection with the applicable termination event valued based on the closing price of our Class A common stock on December 29, 2023, which was $6.07. These amounts reflect probable achievement as of December 29, 2023.

 

Release

 

The obligation of the Company to provide the salary continuation and other severance benefits described above is contingent upon and subject to the execution and delivery by the executive officer of a general release of claims against the Company.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		48

Pay Ratio Disclosure

 

The 2023 annual total compensation of the median compensated of all our employees who were employed as of December 1, 2023, other than our Co-CEOs, Mr. Chintu Patel and Mr. Chirag Patel, was $11,024. The median employee is located in India. Since the Company operated with Co-CEOs for 2023, the annual total compensation of $2,370,386, for Mr. Chirag Patel, which was moderately higher than Mr. Chintu Patel, was used. Had we used Mr. Chintu Patel, our pay ratio would not have changed significantly. The ratio of the compensation of the median employee to Mr. Chirag Patel’s compensation was 1 to 215.

 

The SEC’s rules for identifying the median compensated employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. As a result, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.

 

The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our payroll and employment records and the methodology described below.

 

As of December 1, 2023, we employed approximately 2,420 U.S.-based employees and 5,282 non-U.S. employees. For purposes of calculating our median employee compensation, in addition to excluding our Co-Chief Executive Officers, we excluded all 78 employees from Ireland, which accounted for 1% of our total employee population, using the de minimis exception. For these purposes, we identified the median compensated employee among an employee population of approximately 2,418 U.S. employees (which excludes our Co-CEOs) and 5,204 Indian employees. We identified the median compensated employee using target total cash compensation (comprised of base salary equivalent and target bonus), which we annualized for any employee, other than temporary or seasonal employees, who did not work for the entire year. The average annual exchange rate as of December 1, 2023 was used to convert amounts paid in foreign currencies to U.S. Dollars in order to identify the median employee, while the average annual exchange rate as of December 31, 2023 was used to calculate the 2023 annual total compensation of the median employee.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		49

Pay Versus Performance Disclosure

 

In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown. The sum and/or computation of individual numerical amounts disclosed in the following tables and related footnotes may not equal the total due to rounding.

 

														Value of Initial Fixed $100 Investment based on(4)
Year		Summary Compensation Table Total for Chirag Patel(1) ($)		Summary Compensation Table Total for Chintu Patel(1) ($)		Compensation Actually Paid to Chirag Patel(1)(2)(3) ($)		Compensation Actually Paid to Chintu Patel(1)(2)(3) ($)		Average Summary Compensation Table Total for Non-PEO NEOs(1) ($)		Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) ($)		TSR ($)		Peer Group TSR ($)		Net Income (Loss) ($ Millions)		Adjusted EBITDA ($ Millions)(5)
(a)		(b)		(b)		(c)		(c)		(d)		(e)		(f)		(g)		(h)		(i)
2023		2,370,386		2,367,553		9,458,710		9,455,877		1,679,146		5,801,457		125.93		124.97		(89)		558
2022		5,048,110		5,062,732		(1,835,706)		(1,821,083)		2,348,670		(121,995)		41.29		123.43		(255)		514
2021		4,785,116		4,798,825		1,383,918		1,397,627		2,420,041		1,421,310		99.38		129.31		20		538
2020		2,320,716		2,328,528		3,422,575		3,430,387		1,922,858		1,985,608		94.81		114.32		69		433

(1)	Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.

 

2020	2021	2022	2023
Andrew Boyer	Andrew Boyer	Andrew Boyer	Andrew Boyer
Anastasios Konidaris	Anastasios Konidaris	Anastasios Konidaris	Anastasios Konidaris
Nikita Shah	Nikita Shah	Nikita Shah	Nikita Shah
Joseph Todisco	Joseph Todisco	Jason Daly	Jason Daly
Todd Branning

 

(2)	The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
(3)	Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the amounts from the Stock Awards column set forth in the Summary Compensation Table.

(4)

The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019 (the last trading day of fiscal 2019), through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.

(5)

We determined adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. We may determine a different financial performance measure to be the most important financial performance measure in future years. Adjusted EBITDA is not a term defined under U.S. GAAP. We define adjusted EBITDA as net income before net interest expense, income taxes, and depreciation and amortization (“EBITDA”), as adjusted for certain other items described in our SEC filings, including stock-based compensation expense, acquisition, site closure and idle facility expenses, restructuring and other charges, net charges related to legal matters, asset impairment charges, foreign exchange losses or gains, change in fair value of contingent consideration, and insurance recoveries for property losses and associated expenses. Prior to January 1, 2022, research and development milestone expenses related to license and collaboration agreements were excluded from our calculation of adjusted EBITDA. The amounts shown in this column for the fiscal years ended December 31, 2021 and December 31, 2020 reflect this historical approach. Effective January 1, 2022, we no longer exclude research and development milestone expenses related to license and collaboration agreements from adjusted EBITDA. The amounts shown in this column for the fiscal year ended December 31, 2023 and December 31, 2022 reflect this modified approach; for prior periods, refer to our Form 8-K filed with the Securities and Exchange Commission on May 4, 2022 for a full reconciliation of previously reported non-GAAP results, including adjusted EBITDA, to revised non-GAAP results. As a result of this modified approach, our reported adjusted EBITDA for the fiscal years ended December 31, 2021 and December 31, 2020 was revised to $512 million and $433 million, respectively.

 

(1)	Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.

 

2020	2021	2022	2023
Andrew Boyer	Andrew Boyer	Andrew Boyer	Andrew Boyer
Anastasios Konidaris	Anastasios Konidaris	Anastasios Konidaris	Anastasios Konidaris
Nikita Shah	Nikita Shah	Nikita Shah	Nikita Shah
Joseph Todisco	Joseph Todisco	Jason Daly	Jason Daly
Todd Branning

 

(2)	The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
(3)	Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the amounts from the Stock Awards column set forth in the Summary Compensation Table.

 

Year		Summary Compensation Table Total for Chirag Patel ($)		Exclusion of Stock Awards for Chirag Patel ($)		Inclusion of Equity Values for Chirag Patel ($)		Compensation Actually Paid to Chirag Patel ($)
2023		2,370,386		(664,219)		7,752,544		9,458,710
Year		Summary Compensation Table Total for Chintu Patel ($)		Exclusion of Stock Awards for Chintu Patel ($)		Inclusion of Equity Values for Chintu Patel ($)		Compensation Actually Paid to Chintu Patel ($)
2023		2,367,553		(664,219)		7,752,544		9,455,877

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		50

Back to Contents

Year		Average Summary Compensation Table Total for Non-PEO NEOs ($)		Average Exclusion of Stock Awards and Option Awards for Non- PEO NEOs ($)		Average Inclusion of Equity Values for Non- PEO NEOs ($)		Average Compensation Actually Paid to Non- PEO NEOs ($)
2023		1,679,146		(712,920)		4,835,231		5,801,457

 

The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:

 

Year		Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Chirag Patel ($)		Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Chirag Patel ($)		Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Chirag Patel ($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Chirag Patel ($)		Total - Inclusion of Equity Values for Chirag Patel ($)
2023		3,526,601		4,225,943		—		—		7,752,544
Year		Year-End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Chintu Patel ($)		Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Chintu Patel ($)		Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Chintu Patel ($)		Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Chintu Patel ($)		Total - Inclusion of Equity Values for Chintu Patel ($)
2023		3,526,601		4,225,943		—		—		7,752,544

 

Year		Average Year- End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Non- PEO NEOs ($)		Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($)		Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non- PEO NEOs ($)		Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non- PEO NEOs ($)		Total - Average Inclusion of Equity Values for Non-PEO NEOs ($)
2023		2,996,942		1,838,427		(137)		—		4,835,231

 

(4)

The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019 (the last trading day of fiscal 2019), through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.

(5)

We determined adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. We may determine a different financial performance measure to be the most important financial performance measure in future years. Adjusted EBITDA is not a term defined under U.S. GAAP. We define adjusted EBITDA as net income before net interest expense, income taxes, and depreciation and amortization (“EBITDA”), as adjusted for certain other items described in our SEC filings, including stock-based compensation expense, acquisition, site closure and idle facility expenses, restructuring and other charges, net charges related to legal matters, asset impairment charges, foreign exchange losses or gains, change in fair value of contingent consideration, and insurance recoveries for property losses and associated expenses. Prior to January 1, 2022, research and development milestone expenses related to license and collaboration agreements were excluded from our calculation of adjusted EBITDA. The amounts shown in this column for the fiscal years ended December 31, 2021 and December 31, 2020 reflect this historical approach. Effective January 1, 2022, we no longer exclude research and development milestone expenses related to license and collaboration agreements from adjusted EBITDA. The amounts shown in this column for the fiscal year ended December 31, 2023 and December 31, 2022 reflect this modified approach; for prior periods, refer to our Form 8-K filed with the Securities and Exchange Commission on May 4, 2022 for a full reconciliation of previously reported non-GAAP results, including adjusted EBITDA, to revised non-GAAP results. As a result of this modified approach, our reported adjusted EBITDA for the fiscal years ended December 31, 2021 and December 31, 2020 was revised to $512 million and $433 million, respectively.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		51

Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)

 

The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the four most recently completed fiscal years.

 

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		52

Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income

 

The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income during the four most recently completed fiscal years.

 

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		53

Description of Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Adjusted EBITDA

 

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Adjusted EBITDA during the four most recently completed fiscal years.

 

 

Tabular List of Most Important Financial Performance Measures

 

The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEOs and other NEOs for 2023 to Company performance. The measures in this table are not ranked.

 

Adjusted EBITDA Stock Price

#        #        #

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		54

Proposal 2 Advisory Vote on Executive Compensation

 

Introduction

 

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 enables our stockholders to vote to approve, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC’s rules.

 

As described in detail under the heading “Compensation Discussion and Analysis,” our executive compensation programs, which are guided by the principle of “pay for performance,” are designed to attract, motivate, and retain our named executive officers, reinforce the execution of our business strategy and the achievement of our business objectives, and align the interests of our executive officers with the interests of our stockholders, with the ultimate objective of improving stockholder value. Under these programs, our named executive officers are rewarded for the achievement of annual and long-term goals and the realization of increased stockholder value. Please read the “Compensation Discussion and Analysis” beginning on page 31 for additional details about our executive compensation programs, including information about the fiscal 2023 compensation of our named executive officers.

 

We believe that our compensation program has been instrumental in helping the Company achieve strong financial performance.

 

Therefore, we are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known as a “say on pay” proposal, gives our stockholders the opportunity to express their views on our named executive officers’ compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement.

 

The say on pay vote is advisory, and therefore not binding on our Company, the Compensation Committee or our Board of Directors. However, our Board of Directors and our Compensation Committee value the opinions of our stockholders and will consider the outcome of the vote and the concerns of our stockholders when making future decisions on the compensation of our named executive officers and our Company’s compensation principles, policies and procedures.

 

In accordance with the Board’s policy of holding annual say on pay votes, we expect that the next advisory vote to approve executive compensation will occur at our 2025 Annual Meeting.

 

Required Vote

 

Approval of this proposal requires the affirmative vote of a majority in voting power of the shares of common stock present in person, by remote communication or by proxy at the annual meeting and entitled to vote on the proposal.

 

Recommendation of the Board of Directors

 

THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE PROPOSAL TO APPROVE, IN AN ADVISORY MANNER, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THIS PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SEC.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		55

Security Ownership of Certain Beneficial Owners and Management

 

Beneficial Ownership

 

The following table sets forth information as of March 11, 2024, with respect to the beneficial ownership of our Class A common stock and shows the number of and percentage owned by:

 

•	each person or entity our Company believes to be the beneficial owner of more than five percent of any class of our common stock based solely on management’s review of SEC filings;
•	each named executive officer listed in the summary compensation table;
•	each director; and
•	all of our current directors and executive officers as a group.

 

Beneficial ownership of shares is determined under the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power. Except as indicated by footnote, and subject to applicable community property laws, each person identified in the table possesses sole voting and investment power with respect to all shares of stock held by such person. As of March 11, 2024, 308,554,228 shares of Class A common stock were outstanding.

 

Name(1)		Shares of Common Stock		Options(2)		RSUs(2)		Total		% of Class
Emily Peterson Alva		174,318		53,021		76,453		303,792		*
Deborah M Autor		54,949		—		76,453		131,402		*
Andrew Boyer		319,381		373,033		—		692,414		*
J. Kevin Buchi		185,619		81,397		76,453		343,469		*
Jason B. Daly		57,322		—		—		57,322		*
Jeff George		193,084		28,506		76,453		298,043		*
John Kiely		179,274		28,506		76,453		284,233		*
Anastasios Konidaris		470,386		—		87,719		558,105		*
Paul Meister		620,658		115,156		107,034		842,848		*
Ted Nark		224,318		53,021		76,453		353,792		*
Chintu Patel		25,265,818		53,021		—		25,318,839		8.21
Chirag Patel		21,781,986		53,021		—		21,835,007		7.08
Gautam Patel		1,972,433		53,021		76,453		2,060,860		*
Nikita Shah		391,666		131,856		—		523,522		*
Shlomo Yanai		169,274		28,506		76,453		274,233		*
Total Current Directors and Executive Officers as a Group (15 Persons)		52,060,486		1,052,065		765,330		53,877,881		17.46

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		56

Set forth below is a table demonstrating the ownership of the Amneal Group⁽⁸⁾ as of March 11, 2024:

 

Name(1)		Shares of Class A Common Stock(2)		% of Class
Akram Mahesh(3)		30,384,769		9.85	%
Tushar Patel(4)		53,578,209		17.36	%
Dipan Patel(5)		26,905,073		8.72	%
Chintu Patel(6)		25,318,839		8.21	%
Chirag Patel(7)		21,835,007		7.08	%
Other Members of the Amneal Group		8,113,600		2.63	%
TOTAL AMNEAL GROUP(8)		166,135,497		53.84	%
Set forth below is a table demonstrating the ownership of certain other beneficial owners as of March 11, 2024:
Name		Shares of Class A Common Stock		% of Class
Funds affiliated with Fosun International Limited(9)		18,407,656		5.97	%
Funds affiliated with TPG Inc.(10)		12,328,767		4.00	%

*	Less than 1%
(1)	Unless otherwise noted, the address for each beneficial owner listed on the table is Amneal Pharmaceuticals, Inc., 400 Crossing Boulevard, Bridgewater, NJ 08807.
(2)	Column includes shares underlying exercisable stock options and stock options and restricted stock unit awards that will vest within 60 days of March 11, 2024.
(3)	Akram Mahesh, c/o Tattva Fiduciary Company, 100 West Liberty Street, 10th Floor, Reno, NV 89501. As reported in the Schedule 13G filed by Akram Mahesh on January 4, 2024, Akram Mahesh has the sole power to (a) vote or direct the vote of and (b) dispose or direct the disposition of 30,384,769 shares.
(4)	c/o Tarsadia Investments, LLC, 520 Newport Center Drive, Twenty-First Floor, Newport Beach, CA 92660. Tushar Patel may be deemed to beneficially own 53,578,209 shares of Class A common stock held of record by Tushar Patel Family Trust.
(5)	c/o Buckhead America Hospitality, 2855 Springhill Parkway, Smyrna, GA 30080. Dipan Patel may be deemed to beneficially own 26,905,073 shares of Class A common stock held of record by Dipan Patel Living Trust, AP-1 Trust, AP-2 Trust, AP-3 Trust, AP-5 Trust, AP-7 Trust, and AP-9 Trust.
(6)	Chintu Patel may be deemed to beneficially own 24,753,252 shares of Class A common stock held of record by The Chintu Patel Revocable Trust and The Falguni Patel Revocable Trust.
(7)	Chirag Patel may be deemed to beneficially own 21,269,420 shares of Class A common stock held of record by The Chirag Patel Revocable Trust and The Priti Patel Revocable Trust. Mr. Patel has pledged to Credit Suisse AG 21,269,420 shares of Class A common stock to secure the obligations of those certain borrowers to the Promissory Note and Collateral Agreement dated December 10, 2021 (as modified from time to time).
(8)	See “Corporate Governance – Corporate Structure” above for a discussion of the relationship between the Amneal Group and the Company. Messrs. Chintu Patel, Chirag Patel and Gautam Patel are members of the Amneal Group and also members of our Board, and their shares are reported in the “Executive Officers and Directors” table above. Shares of Class A common stock held by members of the Amneal Group other than Messrs. Akram Mahesh, Chintu Patel, Chirag Patel, Dipan Patel and Tushar Patel are not reported in this table.
(9)	Fosun International Limited, Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong. As reported in the Form 13G/A filed on December 12, 2023 with respect to its holdings as of December 12, 2023, Fosun has the shared power to (a) vote or direct the vote of and (b) dispose or direct the disposition of 18,407,656 shares.
(10)	TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, TX 76102. As reported in the Form 13D/A filed by TPG GP A, LLC on December 14, 2022 with respect to its holdings as of December 12, 2022, the reporting persons have the shared power to vote or direct the vote and the shared power to dispose or direct the disposition of 12,328,767 shares.

 

To our knowledge, except as noted above, no person or entity is the beneficial owner of more than five percent of the voting power of the Company’s stock.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		57

Certain Related Parties and Related Party Transactions

 

Review and Approval of Related Party Transactions

 

Our Board of Directors recognizes that transactions involving our Company and related parties present heightened risk of potential or actual conflicts of interest that may interfere—or even appear to interfere—with the interests of our Company. Therefore, it is the policy of our Company (as set forth in our written Related Person Transaction Policy and Procedures and Conflicts Committee Charter) that the Conflicts Committee of the Board of Directors shall review, approve or ratify any transaction with related parties required to be reported by our Company under the applicable rules and regulations governing related party transactions promulgated by the SEC. As discussed more fully in our Related Person Transaction Policy, in determining whether to approve a transaction, the Conflicts Committee considers all relevant facts and circumstances, including, among other factors, the material terms of the transaction, the approximate dollar value of the amount involved in the transaction, the nature of the related person’s interest in the transaction, the approximate dollar value of the amount of the related person’s direct or indirect interest in the transaction, whether the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party, the importance of the transaction both to the Company and to the Related Person and whether the transaction would likely impair the judgment of a director or executive officer to act in the best interest of the Company. Copies of our Related Person Transaction Policy and Procedures and Conflicts Committee Charter are available on our website.

 

Related Party Transactions

 

See the footnotes to the tables in the section entitled “Security Ownership of Certain Beneficial Owners and Management” for a discussion of related party transactions between the Company and trusts controlled by Chirag Patel relating to pledging arrangements.

 

Fosun International Limited

 

Fosun is a Chinese international conglomerate and investment company that is a stockholder of the Company. On June 6, 2019, the Company entered into a license and supply agreement with a subsidiary of Fosun, which is a Chinese pharmaceutical company. Under the terms of the agreement, the Company will hold the import drug license required for pharmaceutical products manufactured outside of China and will supply Fosun with finished, packaged products for Fosun to then sell in the China market. Fosun will be responsible for obtaining regulatory approval in China and for shipping the product from Amneal’s facility to Fosun’s customers in China. In consideration for access to the Company’s U.S. regulatory filings to support its China regulatory filings and for the supply of product, Fosun paid the Company a $1 million non-refundable fee, net of tax, in July 2019 and will be required to pay the Company $0.3 million for each of eight products upon the first commercial sale of each in China in addition to a supply price and a profit share. On August 11, 2023, the Company and Fosun amended the license and supply agreement to, among other things, (i) increase the products subject to the agreement from eight to ten, (ii) eliminate the first commercial sales milestone of $0.3 million for each product and (iii) decrease the profit share percentage applicable to all products. For the year ended December 31, 2023, the Company recognized $0.1 million in revenue from this agreement.

 

On August 12, 2021, the Company entered into an active pharmaceutical ingredient (“API”) co-development agreement with a subsidiary of Fosun. Under the terms of the agreement, the Company granted Fosun an exclusive license to manufacture and sell two pharmaceutical products outside of the U.S. Fosun will be responsible for obtaining regulatory approvals outside of the U.S. Fosun paid the Company a $0.2 million non-refundable fee, which was recognized in 2021 as revenue and will be required to pay the Company $0.1 million for each of the two products upon the first commercial sale of each in China in addition to a profit share. For the year ended December 31, 2023, the Company did not earn any revenue from this agreement.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		58

TPG Operations LLC and TPG Capital BD, LLC

 

TPG Operations LLC (“TPG”) is a private investment firm that provides financial services and is a significant stockholder of the Company. Jeff Schilling, an observer of our Board, is a managing director of TPG. TPG offers capital and strategic support for companies with substantial growth potential primarily in the healthcare, financial services, real estate, and clean technology sectors.

 

TPG Capital BD, LLC (“TPG Capital”), a subsidiary of TPG, provided the Company with advice and assistance with respect to the refinancing of the Company’s Term Loan. Upon closing of the refinancing in November 2023, the Company paid a success fee of $3.0 million to TPG Capital based on customary market terms.

 

Transactions Involving Our Co-CEOs (Mr. Chirag Patel and Mr. Chintu Patel)

 

Kanan, LLC

 

Kanan, LLC (“Kanan”) is an independent real estate company and the landlord of Amneal’s leased manufacturing facilities located at 65 Readington Road, Branchburg, New Jersey, 131 Chambers Brook Road, Branchburg, New Jersey and 1 New England Avenue, Piscataway, New Jersey, pursuant to certain lease agreements entered into by Amneal and Kanan (the “New Jersey Lease Agreements”). Pursuant to the New Jersey Lease Agreements, rent expense paid to Kanan for the year ended December 31, 2023 was approximately $2.5 million.

 

Chirag Patel and Chintu Patel beneficially own, through certain revocable trusts, 28.0% in the aggregate of the equity securities of Kanan. In addition, each of Chintu Patel and Chirag Patel serves on the Board of Managers of Kanan.

 

Kashiv Biosciences, LLC

 

Kashiv Biosciences, LLC (“Kashiv”) is an independent contract development organization that has historically been focused primarily on the development of 505(b)(2) NDA products utilizing its own proprietary technology platforms, particularly in the areas of abuse deterrence and bioavailability enhancement. Kashiv possesses deep knowledge and patented novel technologies for developing complex generic and specialty products, and Amneal has collaborated with Kashiv to develop a number of those products.

 

In connection with the Acquisition, the Company and Kashiv entered into a Storage Agreement pursuant to which the Company agreed to provide storage and inventory transfer services at the KSP-acquired facility for a period of one year post-Acquisition, which has been extended for an additional one year period. This Storage Agreement expired during 2023 and was not extended.

 

The Company and Kashiv are party to a master services agreement, dated February 20, 2020, covering certain services that Kashiv provides the Company for commercial product support, with such services charged at an hourly rate of $100 per hour for actual time spent plus third party costs.

 

In April 2022, Amneal and Kashiv entered into a consulting agreement whereby Kashiv will provide advice relating to its Specialty programs, with such services to be charged at an hourly rate of $200 per hour for clinical consulting and $240 per hour for non-clinical consulting.

 

In late 2018, Adello Biologics, LLC (“Adello”) contributed substantially all of its assets to Kashiv as of January 1, 2019, and transferred all agreements to Kashiv, including agreements between Amneal and Adello. The following agreements are now between Kashiv and Amneal.

 

Amneal and Kashiv are party to a license and commercialization agreement (the “Kashiv License Agreement”) pursuant to which Kashiv and Amneal have agreed to cooperate with respect to certain development activities in connection with two biologic pharmaceutical products (the “Kashiv Products”). In addition, under the Kashiv License Agreement, Kashiv has appointed Amneal as its exclusive marketing partner for the Kashiv Products in the United States. In connection with the Kashiv License Agreement, Kashiv received an upfront payment of $1.5 million from Amneal in October 2017 and is entitled to share in Amneal’s net profits on the products if and when commercialized. The Kashiv License Agreement provided for potential future milestone payments to Kashiv of up to $183.0 million, as follows: (i) up to $22.5 million relating to regulatory approval and execution, (ii) up to $43.0 million for successful delivery of commercial launch inventory, (iii) up to $50.0 million depending on the number of competitors at launch for one product, and (iv) between $15.0 million and $67.5 million for the achievement of cumulative net sales for both products.

 

In July 2022, the Company and Kashiv amended the Kashiv License Agreement to, among other things, (i) eliminate milestones related to the manufacturing and delivery of the Kashiv products, (ii) revise the net sales milestones to provide for future milestone payments by the Company to Kashiv of up to $37.5 million for the achievement of cumulative combined net sales goals for both products, and (iii) adjust the supply price of product that Kashiv manufacturers and supplies to the Company, which will lower the cost per unit of both products. The remaining milestones are subject to reaching certain commercial sales volume objectives. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs.

 

On May 27, 2022, the FDA approved the biologic license application, associated with the amended Kashiv License Agreement, for Pegfilgrastim-pbbk. In connection with this regulatory approval and associated activity, the Company incurred a milestone of $15.0 million during the third quarter of 2022, which was paid to Kashiv at that time. The milestone was capitalized as an intangible asset and will be amortized to cost of sales over an estimated useful life of 8.3 years.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		59

On May 12, 2023, the Company and Kashiv amended the Kashiv License Agreement to provide for, among other things, (i) Kashiv to have the right to develop either or both an auto-injector delivery system or an on-body injector for the biosimilar PEG-filgrastim, and (ii) the Company to have a right of first negotiation to launch and commercialize either or both of such products.

 

In August 2020, Amneal and Kashiv entered into a product development agreement for the development and commercialization of two generic peptide products, Ganirelix Acetate and Cetrorelix Acetate. Under the agreement, the intellectual property and ANDA for these products are owned by Amneal, and Kashiv is to receive a profit share for all sales of the products made by Amneal.

 

Pursuant to the agreements described above, total payments for milestones, services and reimbursement of expenses paid to Kashiv for the year ended December 31, 2023 was $5.1 million. As of December 31, 2023, the Company has $1.0 million of inventory on hand associated with the amended Kashiv License Agreement. In addition, as of December 31, 2023, $3.2 million was outstanding and payable to Kashiv.

 

In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal will be responsible for manufacturing batch products, as well as to perform certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, will be responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Kashiv is also responsible to reimburse Amneal for sourcing developmental materials at cost. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services. For the year ended December 31, 2023, the Company recognized $2.8 million related to reimbursable costs associated with developmental work for this agreement, as a reduction to research and development expenses.

 

The Company and Kashiv are also party to an arrangement whereby the Company leases parking spaces from Kashiv, pursuant to which the Company pays to Kashiv approximately $99,000 per year.

 

Chirag Patel and Chintu Patel beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, 50% in the aggregate of the outstanding equity securities of Kashiv. In addition, each of Chintu Patel and Chirag Patel serve on the Board of Managers of Kashiv.

 

Nava Pharma, LLC and PharmaSophia, LLC

 

PharmaSophia, LLC (“PharmaSophia”) is a joint venture formed by Nava Pharma, LLC (“Nava”) and Oakwood Laboratories, LLC for the purpose of developing certain products. PharmaSophia is currently actively developing one injectable product. PharmaSophia and Nava are parties to a research and development agreement pursuant to which Nava provides research and development services to PharmaSophia. Nava subcontracted this obligation to Amneal. Amneal, PharmaSophia and Oakwood also entered into a manufacturing agreement whereby Amneal agreed to manufacture exhibit and commercial batches of products under development.

 

In October 2022, PharmaSophia and Amneal entered into an exclusive license and commercialization agreement (the “PharmaSophia Agreement”) to develop, manufacture, and sell one injectable product. Under the terms of the agreement, Amneal committed to spend up to $6.0 million to further develop the product, including all related expenses up to submission of the ANDA, which will be owned by Amneal. In addition, under the terms of the PharmaSophia Agreement, PharmaSophia settled a liability of $1.1 million payable to Amneal under the terms of the Nava Agreement by reducing the amount of Amneal’s committed spending under the terms of the PharmaSophia Agreement to $4.9 million. PharmaSophia will receive a 50% profit share for all sales of product made by Amneal under the PharmaSophia Agreement.

 

Chirag Patel and Chintu Patel beneficially own, directly and through certain revocable trusts, equity securities in Nava. Nava beneficially owns 50% of the outstanding equity securities of PharmaSophia. In addition, each of Chintu Patel and Chirag Patel serve on Nava and PharmaSophia’s Board of Managers.

 

Avtar Investments, LLC and Avtar Enterprise, LLC

 

Avtar Investments, LLC is a private investment firm and Avtar Enterprise, LLC is a private portfolio company (collectively, “Avtar”). Chirag Patel and Chintu Patel beneficially own, directly and through certain revocable trusts, outstanding equity securities of Avtar. In July 2020, the Company entered into an agreement with Avtar Enterprise under which Avtar agreed to provide consulting services relating to certain clinical studies and regulatory advice for generic pharmaceutical products in development by the Company. Avtar and Amneal amended the agreement in 2022 to include several inhalation products and specialty programs. For the year ended December 31, 2023, the Company recorded $0.3 million in expenses related to the consulting agreement. As of December 31, 2023, $0.1 million was due to Avtar.

 

Employment and Stockholder Arrangements with Immediate Family Members

 

Kanubhai Patel, the father of Chirag and Chintu Patel, is employed by us and serves as an operational and strategic advisor to the Company and its Indian subsidiaries, including but not limited to Amneal Pharmaceuticals India Private Limited. During the fiscal year ended December 31, 2023, Mr. Kanubhai Patel had total cash compensation of approximately $458,428. In addition, he received a long-term incentive award in 2024 with a determined value of $195,000.

 

Bindu Patel, a sister of Chirag and Chintu Patel, is employed by us as a manager in the information technology department. During the fiscal year ended December 31, 2023, Ms. Bindu Patel had total compensation of approximately $159,494.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		60

The Reorganization

 

As disclosed above under “Corporate Governance—Corporate Structure, Reorganization and Transfer of Listing Exchange,” on November 7, 2023, we implemented a plan pursuant to which the Company and Amneal LLC reorganized and we simplified our corporate structure by eliminating our umbrella partnership-C-corporation structure and converting to a more traditional structure whereby all stockholders hold their voting and economic interests directly through the public company, which we refer to as the Reorganization. Effective with the Reorganization, the Company holds directly or indirectly 100% of the Amneal Common Units and the Company remains Amneal LLC’s sole managing member, having the sole voting power to make all of Amneal LLC’s business decisions and control its management. Following the implementation of the Reorganization, Amneal Intermediate, Inc., a Delaware corporation (formerly known as Amneal Pharmaceuticals, Inc.) (for purposes of the Reorganization, “Old Amneal”), became a wholly-owned subsidiary of a new holding company, Amneal Pharmaceuticals, Inc., a Delaware corporation (formerly known as Amneal NewCo Inc.) (for purposes of the Reorganization, “New Amneal”).

 

Organizational Agreements and Documents

 

To effectuate the Reorganization, we entered into and/or amended various organizational agreements and documents, including agreements and plans of merger, certificates of incorporation and bylaws.

 

Assumption of Old Amneal Equity Plan and Agreements

 

In connection with the Reorganization, on November 7, 2023, New Amneal assumed the 2018 Incentive Award Plan and all outstanding stock options and equity awards granted thereunder as well as the indemnification agreements between Old Amneal and the directors and executive officers of Old Amneal, in each case to make administrative amendments related to the Reorganization.

 

Letter Agreement Amendments to Executive Employment Agreements

 

In connection with the Reorganization, on November 7, 2023, each of (i) the Boyer Employment Agreement, (ii) the Konidaris Employment Agreement, and (iii) the Shah Employment Agreement was amended. For further details, please refer to “Executive Compensation—Management Employment & Separation Agreements” herein.

 

Stock Surrender Agreement

 

In connection with the Reorganization, the Company and each member of the Amneal Group entered into a Stock Surrender Agreement, dated as of November 7, 2023 (“Stock Surrender Agreement”) which had the effect of each member of the Amneal Group agreeing to irrevocably surrender to the Company each share of Old Amneal Class B Common Stock held by such Amneal Group member immediately prior to the Reorganization.

 

Other Agreements

 

In connection with the Reorganization, the Company entered into amendments to other agreements that are described more fully in this section.

 

Expenses

 

We incurred approximately $5.9 million in expenses related to the Reorganization during the year ended December 31, 2023, comprised of professional fees.

 

Agreements Entered into in Connection with the Combination and the PIPE Investment

 

In 2018, Amneal entered into an important strategic transaction that we refer to as the Combination. The Combination was a transformative event that established Amneal as an industry leader with high-value generic product pipelines and a growing specialty business. The following summarizes the agreements we entered in connection with the Combination.

 

Stockholders Agreement

 

See the “Corporate Governance” section of this proxy statement for a summary of the material terms of the Stockholders Agreement. In connection with the Reorganization, on November 7, 2023, Old Amneal amended and restated the Stockholders Agreement in order to facilitate the Reorganization.

 

PIPE Investment

 

In connection with the Combination, on May 4, 2018, members of the Amneal Group entered into definitive purchase agreements (the “PIPE Purchase Agreement”) that provided for a private placement of certain shares of Class A common stock and Class B-1 common stock (the “PIPE Investment”) with select institutional investors (the “PIPE Investors”). Pursuant to the PIPE Purchase Agreement, upon the closing of the Combination (the “Closing”), members of the Amneal Group exercised their right to cause Amneal LLC to redeem units held by such members pursuant to the Third Amended and Restated LLC Agreement (dated as of May 4, 2018 and defined herein). In connection with such redemption, such members of the Amneal Group received shares of Class A common stock or shares of Class B-1 common stock

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		61

in exchange for such redeemed units, in each case pursuant to the LLC Agreement (such redemption and issuance of Class A common stock and Class B-1 common stock to the members of the Amneal Group, the “Redemption”). Following the Redemption, the members of the Amneal Group sold such shares of Class A common stock and Class B-1 common stock to the PIPE Investors at a per share purchase price of $18.25 for gross proceeds of approximately $855,000,000. Following the PIPE Investment, the PIPE Investors owned collectively approximately 15% of the Company’s shares on a fully diluted and as converted basis, with TPG owning all outstanding shares of Class B-1 common stock. As a result of the Conversion in 2019, there are no longer any shares of Class B-1 common stock outstanding.

 

In connection with the Combination and in furtherance of the PIPE Investment, TPG, the Amneal Group and the Company entered into the PIPE Side Letter providing for certain rights and obligations of each in connection with the PIPE Investment. Pursuant to the PIPE Side Letter, TPG has customary registration rights with respect to the Company’s shares owned by TPG. The PIPE Side Letter also provides TPG the right to designate a Board observer with respect to the Company’s Board of Directors, as well as the right, subject to certain ownership thresholds discussed herein, to designate a director for appointment to the Company’s Board of Directors.

 

Registration Rights Agreement

 

We entered into a Registration Rights Agreement with the PIPE Investors in connection with the Closing. The Registration Rights Agreement provides the PIPE Investors certain registration rights whereby the Company and Impax were required to jointly prepare and file with the SEC a shelf registration statement on Form S-1 with respect to resales of all shares of Class A common stock beneficially owned by the Amneal Group. We agreed to use our reasonable best efforts to become eligible to use Form S-3 and, upon becoming eligible, we agreed to promptly file a shelf registration statement on Form S-3.

 

Tax Receivable Agreement

 

Pursuant to the LLC Agreement, in effect at the Combination, the Amneal Group and its permitted transferees had the right to redeem all or a portion of their Amneal Common Units (defined herein) for Class A common stock. In connection with such redemption, Old Amneal received a “step-up” in its share of the tax basis in the Amneal LLC assets, and Old Amneal agreed to pay the Members (as defined below) for the value of such benefits.

 

In connection with the Reorganization, on November 7, 2023, Old Amneal amended that certain Tax Receivable Agreement, dated as of May 4, 2018 (as amended, the “Tax Receivable Agreement”), among Old Amneal and the Amneal Group (such amendment, the “TRA Amendment”), in order to (i) provide that the percentage of the applicable tax savings the Amneal Group will be entitled to thereunder is decreased from 85% to 75% and (ii) facilitate the Reorganization.

 

The following summary of the terms of the Tax Receivable Agreement is not a complete description thereof and is qualified in its entirety by the full text thereof.

 

The Tax Receivable Agreement continues to govern the administration and allocation between the parties of tax liabilities and benefits arising prior to, as a result of, and subsequent to the Combination, and the respective rights, responsibilities and obligations of the Members and the Company with respect to various other tax matters. The term “Members” includes the then existing members of Amneal LLC at Closing (other than Old Amneal) and any persons who have executed and delivered a joinder in accordance with the Tax Receivable Agreement. Chirag Patel, Chintu Patel and Gautam Patel are Members.

 

Determination of Realized Tax Benefit

 

Under the Tax Receivable Agreement, the Company and Old Amneal will ensure that Amneal LLC and its subsidiaries that are treated as a partnership for U.S. federal income tax purposes will have in effect an election under Section 754 of the Code.

 

Basis Schedules

 

Within 90 days after the filing of the U.S. federal income tax return of Old Amneal for each relevant taxable year, Old Amneal will at its own expense deliver to the Members a schedule that shows (a) the basis adjustments with respect to the reference assets as a result of the relevant exchanges through the Reorganization, calculated (i) in the aggregate and (ii) solely with respect to exchanges by the applicable Member; (b) the period (or periods) over which the reference assets are amortizable and/or depreciable; and (c) the period (or periods) over which each basis adjustment is amortizable and/or depreciable.

 

Tax Benefit Schedules

 

Within 90 days after the filing of the U.S. federal income tax return of Old Amneal for any taxable year in which there is a realized tax benefit or realized tax detriment, Old Amneal shall, at its own expense, deliver to the Members a schedule showing the calculation of the realized tax benefit or realized tax detriment for such taxable year.

 

Tax Benefit Payments

 

Each Member is entitled to receive an amount equal to the sum of (1) 75% of the cumulative net realized tax benefit attributable to such Member as of the end of such taxable year over the aggregate amount of all tax benefit payments previously made to such Member, and (2) the interest calculated at the agreed rate from the due date for filing the U.S. federal income tax return of Old Amneal for such taxable year until the date on which Old Amneal makes a timely tax benefit payment to the Member.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		62

Termination

 

Old Amneal may terminate the Tax Receivable Agreement with the written approval of a majority of the independent directors of the Company’s Board of Directors by making a payment to the Members, equal to the present value of the tax benefit payments to be paid to each such Member, discounted at the lesser of ICE LIBOR plus 100 basis points or 6.50% per annum, compounded annually (an “Early Termination Payment”). The Tax Receivable Agreement will also be deemed to be terminated by Old Amneal and an Early Termination Payment by Old Amneal will be required in the event of either (a) a Change of Control (as defined below) or (b) a material breach by Old Amneal of any of its material obligations under the Tax Receivable Agreement.

 

A “Change of Control” includes (a) any person other than the Amneal Group and their permitted transferees beneficially owning more than 50% of the combined voting power of the Company; (b) the liquidation or dissolution of the Company, or the sale of all or substantially all of the assets of the Company, unless the sale is to an entity of which at least 50% of the combined voting power is owned by the Company’s Stockholders who owned the Company immediately prior to such sale in substantially the same proportions; (c) a business combination of the Company or any of its subsidiaries with any other entity, after which the Company’s Board of Directors immediately prior to such combination does not constitute at least a majority of the Board of Directors of the surviving company or its parent, or all of the beneficial owners of the voting securities of the Company prior to such combination do not beneficially own more than 50% of the combined voting power of the surviving entity; and (d) the following individuals ceasing to constitute a majority of the Company’s Board of Directors: (i) the directors of the Company as of November 7, 2023 (“Initial Directors”) and (ii) any new director whose appointment or nomination was approved by at least two-thirds of the directors who were (x) Initial Directors or (y) whose appointment or nomination was approved by at least two-thirds of the Initial Directors.

 

LLC Agreement

 

In connection with the Combination, Amneal LLC, the Company and the Existing Amneal Members (and the Amneal Group following the assignment and transfer by the Existing Amneal Members (as defined in the LLC Agreement) of Amneal Common Units to the Amneal Group) entered into and are governed by the LLC Agreement, which sets forth, among other things, certain transfer restrictions on Amneal Common Units, and rights to redeem Amneal Common Units in certain circumstances. The following summary of the terms of the LLC Agreement is not a complete description thereof and is qualified in its entirety by the full text thereof. Undefined capitalized terms in this section have the meaning ascribed to them in the LLC Agreement.

 

In connection with the Reorganization, on November 7, 2023, Amneal LLC entered into the Fourth A&R LLC Agreement, in order to (i) remove the requirement for Amneal LLC to make tax distributions, (ii) reflect the addition of New Amneal as a member and the removal as members of the former holders of Old Amneal Class B Common Stock after conversion of the Common Units paired with Old Amneal Class B Common Stock to New Amneal Class A common Stock and (iii) to facilitate the Reorganization.

 

Appointment of the Company as Manager

 

Under the LLC Agreement, the Company is admitted as the sole managing member of Amneal LLC. As the managing member, the Company will conduct, direct and exercise full control over all activities of Amneal LLC, including day-to-day business affairs and decision-making of Amneal LLC, without the approval of any other member. As such, the Company, through Amneal’s LLC officers, will be responsible for all operational and administrative decisions of Amneal LLC and the day-to-day management of Amneal’s LLC business.

 

Pursuant to the terms of the LLC Agreement, the Company will not be permitted, under any circumstances, to be removed as managing member by the members of Amneal LLC. The Company will not resign or cease to be the managing member unless proper provision is made for the obligations of the Company to remain in full force and effect.

 

The managing member may cause Amneal LLC to contract with the managing member or any affiliate of the managing member as long as the contracts are on terms comparable to those available to others dealing at arm’s length or are approved by the members (other than the managing member and its controlled affiliates) holding a majority of the Amneal Common Units.

 

Officers

 

The managing member will appoint the officers of Amneal LLC to implement the day-to-day business and operations of Amneal LLC. In the event of a vacancy, the managing member has the right to appoint a new officer to fill the vacancy.

 

Compensation

 

The Company will not be entitled to compensation for its services as managing member. It will be entitled to reimbursement by Amneal LLC for reasonable fees and expenses incurred on behalf of Amneal LLC, except for payment obligations of the Company under the Tax Receivable Agreement.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		63

Report of the Audit Committee

 

Under the guidance of a written charter adopted by our Board of Directors, the Audit Committee oversees our management’s conduct of the financial reporting process on behalf of the Board of Directors. A copy of the charter is available at the investor relations section of our company’s website, http://investors.amneal.com. The Audit Committee also appoints the independent registered public accounting firm to be retained to audit our company’s consolidated financial statements and internal control over financial reporting, and once retained, the independent registered public accounting firm reports directly to the Audit Committee. The Audit Committee is responsible for pre-approving both audit and non-audit services to be provided by the independent registered public accounting firm. The Audit Committee’s charter reflects the above-mentioned responsibilities, and the Audit Committee and the Board of Directors periodically review and revise the charter.

 

Management is responsible for our company’s financial reporting process, including the system of internal controls, and for the preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Our company’s independent registered public accounting firm is responsible for auditing those consolidated financial statements and expressing an opinion on the conformity of the consolidated financial statements with accounting principles generally accepted in the United States of America. In addition, our company’s independent registered public accounting firm will express its own opinion on the effectiveness of the company’s internal control over financial reporting. The Audit Committee’s responsibility is to monitor and review these processes. It is not the Audit Committee’s duty or responsibility to conduct auditing or accounting reviews.

 

The Audit Committee meets at least four times annually, or more frequently as circumstances dictate. During fiscal 2023, the Audit Committee met five times. The Audit Committee also met with management periodically to consider the adequacy of our company’s internal controls, and discussed these matters and the overall scope and plans for the audit of our company with our independent registered public accounting firm, Ernst & Young LLP. The Audit Committee met with the independent registered public accounting firm, with and without management present, to discuss the results of its examination, its evaluation of the effectiveness of our internal control over financial reporting, and the overall quality of our financial reporting. The Audit Committee also discussed with senior management our company’s disclosure controls and procedures and the certifications by our co-chief executive officers and chief financial officer, which are required by the SEC under the Sarbanes-Oxley Act of 2002 for certain of our company’s filings with the SEC. The Audit Committee also met separately from time to time with our chief financial officer and, at least quarterly, the Audit Committee met in executive session.

 

In fulfilling its oversight responsibilities, the Audit Committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated financial statements in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, management’s assessment of the effectiveness of our company’s internal control over financial reporting and the independent registered public accounting firm’s evaluation of the effectiveness of our company’s internal control over financial reporting as of December 31, 2023. The Audit Committee reviewed with the independent registered public accounting firm, who is responsible for expressing an opinion on the conformity of the consolidated financial statements with accounting principles generally accepted in the United States of America, its judgments as to the quality, not just the acceptability, of our company’s accounting principles, the reasonableness of significant judgments and the clarity of disclosures in the financial statements and such other matters as are required to be discussed with the Audit Committee under auditing standards of the Public Company Accounting Oversight Board (PCAOB). In addition, the Audit Committee has discussed with the independent registered public accounting firm its independence from our company and our management, including the matters in the written disclosures and letter which were received by the Audit Committee from the independent registered public accounting firm as required by the applicable requirements of the PCAOB, and considered the compatibility of non-audit services with Ernst & Young LLP’s independence. In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors (and the board approved) that the audited consolidated financial statements be included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 for filing with the SEC.

 

Audit Committee:
John Kiely (Chair)
Deb Autor
J. Kevin Buchi
Jeff George

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		64

Proposal 3 Appointment of Independent Registered Public Accounting Firm

 

Introduction

 

The Audit Committee has appointed Ernst & Young LLP as the independent registered public accounting firm to audit our consolidated financial statements and the effectiveness of our internal control over financial reporting for the fiscal year ending December 31, 2024.

 

We are asking our stockholders to ratify the selection of Ernst & Young as our independent registered public accounting firm. Although ratification is not required by our Bylaws or otherwise, our Board of Directors is submitting the selection of Ernst & Young to our stockholders for ratification as a matter of good corporate practice. If the selection is not ratified, the Audit Committee will consider whether it is appropriate to select another registered public accounting firm. Even if the selection is ratified, the Audit Committee in its discretion may select a different registered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and our stockholders.

 

One or more representatives of Ernst & Young are expected to be present at the annual meeting. They will have an opportunity to make a statement if they desire to do so and are expected to be available to respond to appropriate stockholder questions.

 

Independent Registered Public Accounting Firm Fees

 

In addition to performing the audit of our consolidated financial statements, Ernst & Young has provided various other services during fiscal 2023 and 2022. The aggregate fees billed or expected to be billed for fiscal 2023 and 2022 for each of the following categories of services are as follows:

 

Type of Fees		Fiscal 2023			Fiscal 2022
Audit Fees		$	5,748,100		$	4,553,300
Audit-Related Fees			100,000			200,000
Tax Fees			352,700			423,300
All Other Fees			7,200			3,000
TOTAL		$	6,208,000		$	5,179,600

 

In accordance with the SEC’s definitions and rules, the terms in the above table have the following meanings:

 

“Audit Fees” are the aggregate fees billed or expected to be billed for each of fiscal 2023 and 2022 for professional services rendered by Ernst & Young for the audit of our consolidated financial statements included in our annual reports on Form 10-K and review of the unaudited consolidated financial statements included in our quarterly reports on Form 10-Q; SEC registration statements, including consents and review of documents filed with the SEC, consultation on accounting standards or transactions, and for services in connection with statutory or regulatory filings or engagements; and for services that are normally provided by Ernst & Young in connection with statutory and regulatory filings or engagements for fiscal 2023 and 2022.

 

“Audit-Related Fees” are the aggregate fees billed in fiscal 2023 and 2022 for assurance and related services by Ernst & Young that are reasonably related to the performance of the audit or review of our consolidated financial statements.

 

“Tax Fees” are the aggregate fees billed in each of fiscal 2023 and 2022 for professional services rendered by Ernst & Young for tax compliance, tax advice and tax planning.

 

“All Other Fees” are the aggregate fees billed in each of fiscal 2023 and 2022 for products and services provided by Ernst & Young not included in the first three categories.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		65

The Audit Committee has reviewed summaries of the services provided by Ernst & Young and the related fees, and the Audit Committee has determined that the provision of the non-audit services described above is compatible in maintaining the independence of Ernst & Young.

 

All of the services described above that required pre-approval were pre-approved by the Audit Committee in accordance with its pre-approval policy. The Audit Committee pre-approval policy provides that all auditing services and all non-audit services to be provided by Ernst & Young be pre-approved by the Audit Committee, provided that the Audit Committee shall not approve any non-audit services prohibited by Section 10A(g) of the Exchange Act.

 

Required Vote

 

Ratification of the appointment of our independent registered public accounting firm requires the affirmative vote of a majority in voting power of the shares of common stock present in person, by remote communication or by proxy at the annual meeting and entitled to vote on the proposal.

 

Recommendation of the Board of Directors

 

THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		66

Other Matters

 

Our management is not aware of any other matters to be presented for action at the annual meeting; however, if any such matters are properly presented for action, it is the intention of the proxy appointees to vote in accordance with their best judgment on such matters.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		67

About the Meeting

 

Why am I receiving these materials?

 

This proxy statement is provided to the stockholders of the Company as of the close of business on March 11, 2024 (the “Record Date”) in connection with the solicitation of proxies by our Board of Directors to be voted at our annual meeting of stockholders to be held virtually at www.virtualshareholdermeeting.com/AMRX2024 at 9:00 a.m., Eastern Daylight Time, on Thursday, May 2, 2024, and at any adjournment or postponement of the meeting. This proxy statement provides important information that you should consider in deciding how to vote on the matters to be voted on at the annual meeting.

 

Why is the annual meeting being webcast online?

 

This year, the annual meeting will be a virtual meeting of stockholders held via a live audio webcast. The format of the virtual meeting has been designed to ensure that our stockholders who attend our annual meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting and to enhance stockholder access, participation and communication through online tools. Stockholders will be able to present questions online during the meeting through www.virtualshareholdermeeting.com/AMRX2024, providing our stockholders with the opportunity for meaningful engagement with the Company. In addition, stockholders will be permitted to submit a question in advance of the meeting at www.proxyvote.com after logging in with your 16-digit Control Number.

 

How do I participate in the virtual meeting?

 

Our annual meeting will be a completely virtual meeting of stockholders, which will be conducted exclusively by live audio webcast. No physical in-person meeting will be held.

 

The online meeting will begin promptly at 9:00 a.m. EDT. We encourage you to access the meeting prior to the start time leaving ample time for the check in. To participate in the meeting, you must have your 16-digit Control Number that is shown on your Notice or, if you received a printed copy of the proxy materials, on your proxy card or the instructions that accompanied your proxy materials. You may access the annual meeting online, vote and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/AMRX2024. Stockholders will be able to submit questions during the meeting by typing in your question into the “ask a question” box on the meeting page. If you lose your 16-digit Control Number, you may join the annual meeting as a “guest” but you will not be able to vote, ask questions or access the list of stockholders as of the close of business on the Record Date.

 

Will I be able to participate in the virtual meeting on the same basis as I would be able to participate in a live meeting?

 

The virtual meeting format for the annual meeting will enable full and equal participation by all of our stockholders from any place in the world at little to no cost.

 

The format of the virtual meeting has been designed to ensure that our stockholders who attend our annual meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting and to enhance stockholder access, participation and communication through online tools. We will take the following steps to ensure such an experience:

 

•	providing stockholders with the ability to submit appropriate questions in advance of the meeting to ensure thoughtful responses;
•	providing stockholders with the ability to submit appropriate questions real-time via the meeting website, limiting questions to one per stockholder unless time otherwise permits; and
•	answering as many questions submitted in accordance with the meeting rules of conduct as possible in the time allotted for the meeting without discrimination.

 

Questions pertinent to meeting matters will be answered during the meeting, subject to time constraints. Questions regarding personal matters, including those related to employment issues, are not pertinent to meeting matters and therefore will not be answered.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		68

What if during the check-in time or during the meeting I have technical difficulties or trouble accessing the virtual meeting website?

 

Should you require technical assistance, support will be available by dialing 1-844-986-0822 (U.S.) or 1-303-562-9302 (International) during the meeting; these telephone numbers will also be displayed on the meeting webpage. If there are any technical issues in convening or hosting the meeting, we will promptly post information to our website, including information on when the meeting will be reconvened.

 

What items will be voted on at the annual meeting?

 

At the annual meeting, the stockholders will consider and vote upon:

 

•	the election of 11 directors named in this proxy statement to hold office until the next annual meeting of stockholders (Proposal No. 1);
•	an advisory vote to approve executive compensation, commonly referred to as a “say on pay” proposal (Proposal No. 2); and
•	the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2024 (Proposal No. 3).

 

If you received a paper copy of these materials by mail, the proxy materials also include a proxy card or a voting instruction card for the annual meeting.

 

What is a proxy statement? What information is contained in this proxy statement?

 

It is a document that SEC regulations require us to give you when we ask you to designate proxies to vote on your behalf. The information in this proxy statement relates to the proposals to be voted on at the annual meeting, the voting process, the Company’s Board of Directors and Board committees, the compensation of our directors and executive officers for fiscal 2023 and other required information.

 

Why did I receive a notice in the mail regarding the Internet availability of the proxy materials instead of a paper copy of the proxy materials?

 

We are pleased to be using the SEC rule that allows companies to furnish their proxy materials to stockholders over the Internet. As a result, we are mailing to most of our stockholders a Notice of Internet Availability of the proxy materials instead of a paper copy of the proxy materials. We believe that this process allows us to provide our stockholders with the information they need in a timelier manner, while reducing the environmental impact and lowering the costs of printing and distributing our proxy materials. All stockholders receiving the notice will have the ability to access the proxy materials over the Internet and request to receive a paper copy of the proxy materials by mail.

 

How can I access the proxy materials over the Internet?

 

The notice of annual meeting, proxy statement and annual report are available at www.proxyvote.com. Instead of receiving future copies of the proxy materials by mail, most beneficial owners can elect to receive an email that will provide electronic links to these documents. Opting to receive your proxy materials online will save us the cost of producing and mailing documents to your home or business and will also give you an electronic link to the proxy voting site. If you received a Notice of Internet Availability, that notice will contain additional instructions on how to view our proxy materials on the Internet.

 

How may I obtain a paper copy of the proxy materials?

 

Stockholders receiving a Notice of Internet Availability will find instructions about how to obtain a paper copy of the proxy materials on that notice. All stockholders who do not receive a notice will receive a copy of the proxy materials by mail or email.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		69

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

 

If your shares are registered directly in your name with the Company’s registrar and transfer agent, Computershare, you are considered a stockholder of record with respect to those shares.

 

If your shares are held in a brokerage account or with a bank or other nominee, you are considered the “beneficial owner” of those shares.

 

Who is entitled to vote at the annual meeting?

 

Each holder of record of our Class A common stock at the close of business on the Record Date is entitled to vote at the annual meeting (Class A common stock is referred to herein as the “voting common stock”). As of the Record Date, a total of 308,554,228 shares of Class A common stock were outstanding and are eligible to vote at the annual meeting. Each share of our Class A common stock is entitled to one vote per share on all matters with respect to which holders are entitled to vote.

 

How do I vote during the meeting?

 

We will be hosting the annual meeting live online. You can participate in the annual meeting live online at www.virtualshareholdermeeting. com/AMRX2024. The webcast will start at 9:00 a.m. EDT. Stockholders may vote and submit questions while attending the meeting online. You will need the 16-digit Control Number included on your Notice or, if you received a printed copy of the proxy materials, on your proxy card or the instructions that accompanied your proxy materials in order to be able to vote and submit questions during the meeting.

 

Your shares may only be voted at the annual meeting if you are present by remote communication or are represented by proxy. Whether or not you plan to attend the annual meeting, we encourage you to vote by proxy in advance of the annual meeting to assure that your shares will be represented. Voting by proxy will in no way limit your right to vote at the annual meeting if you later decide to participate in the online meeting. Only your latest executed vote will count.

 

How do I vote my shares in advance without attending the Annual Meeting?

 

If you are a stockholder of record, you may vote by granting a proxy. Specifically, you may vote:

 

•	By Internet: If you have Internet access, you may submit your proxy by going to www.proxyvote.com and by following the instructions on how to complete an electronic proxy card. You will need the 16-digit number included on your Notice of Internet Availability or your proxy card in order to vote by Internet.
•	By Telephone: You may submit your proxy by dialing 1-800-690-6903 and by following the recorded instructions. You will need the 16-digit number included on your Notice of Internet Availability or your proxy card in order to vote by telephone.
•	By Mail: You may vote by mail by requesting a proxy card from us, indicating your vote by completing, signing and dating the card where indicated and by mailing or otherwise returning the card in the envelope that will be provided to you. You should sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity (for example, as guardian, executor, trustee, custodian, attorney or officer of a corporation), indicate your name and title or capacity.

 

If you hold your shares in street name, you may submit voting instructions to your broker, bank or other nominee. In most instances, you will be able to do this over the Internet, by telephone or by mail. Please refer to information from your bank, broker or other nominee on how to submit voting instructions.

 

What can I do if I change my mind after I vote my shares?

 

Stockholders of Record

 

If you are a stockholder of record, you may revoke your proxy at any time before it is exercised by timely submission of a written revocation to our corporate secretary at our principal executive offices located at 400 Crossing Boulevard, Bridgewater, New Jersey 08807, submission of a properly executed later-dated proxy, or by voting online at the annual meeting. Attendance at the annual meeting will not by itself constitute a revocation of a proxy.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		70

Beneficial Owners

 

If your shares are held in the name of a broker, bank or other holder of record, that institution will instruct you as to how your vote may be changed and the deadline for doing so.

 

If I am a stockholder of record, how will my shares be voted if I sign, date and return my proxy card? What if I do not specify a choice for a matter when returning my signed proxy card?

 

All shares entitled to vote that are represented by properly completed proxy cards received prior to the annual meeting and not revoked will be voted at the meeting in accordance with your instructions. If you sign and return a proxy card but do not indicate how your shares should be voted, the shares represented by your proxy card will be voted in accordance with the Board of Directors’ recommendations on Proposals 1-3 and in the discretion of the persons designated as proxies as to any other matter that may properly come before the annual meeting.

 

What if I am a beneficial owner and do not give voting instructions to my broker?

 

As a beneficial owner, to make sure your shares are voted in the way you would like, you must provide voting instructions to your bank, broker or other nominee by the deadline provided in the materials you receive from your bank, broker or other nominee.

 

If you do not provide voting instructions to your bank, broker or other nominee, your shares cannot be voted on any “non-routine” matters, which is commonly referred to as a “broker non-vote.”

 

Under current interpretations that govern broker non-votes, Proposal Nos. 1 and 2 are considered non-routine matters, and a broker will lack the authority to vote uninstructed shares at their discretion on such proposals. Proposal No. 3 is considered a routine matter, and a broker will be permitted to exercise its discretion to vote uninstructed shares on the proposal.

 

What constitutes a quorum?

 

The presence by remote communication or represented by proxy of the holders of a majority of the issued and outstanding shares of stock entitled to vote at the meeting shall constitute a quorum for the transaction of business. Abstentions and broker non-votes will be counted as present and entitled to vote for purposes of determining a quorum. A broker “non-vote” occurs when a nominee, such as a bank or broker, holding shares for a beneficial owner, does not vote on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner (see “What if I am a beneficial owner and do not give voting instructions to my broker?” above).

 

How will votes be counted?

 

With respect to Proposal No. 1, to be elected, a nominee for director must receive the affirmative vote of a majority of the votes cast with respect to such nominee by the holders of the shares of common stock voting in person, by remote communication or by proxy at the annual meeting. Approval of each of Proposal Nos. 2 and 3 requires the affirmative vote of a majority in voting power of the shares of common stock present in person, by remote communication or by proxy at the annual meeting and entitled to vote on the subject matter. Abstentions will not affect the outcome of the vote for Proposal No. 1 but will have the same effect as a vote “AGAINST” for Proposal Nos. 2 and 3. Broker non-votes will not affect the outcome of the vote for Proposal Nos. 1 through 3.

 

Who will count the votes?

 

A representative of American Election Services LLC will tally the vote and serve as inspector of the annual meeting.

 

How are proxies being solicited and who will pay for the solicitation of proxies?

 

We will bear the expense of the solicitation of proxies. In addition to the solicitation of proxies by mail, solicitation may be made by our directors, officers and employees by other means, including telephone, over the Internet or in person. No special compensation will be paid to our directors, officers or employees for the solicitation of proxies. To solicit proxies, we will also request the assistance of brokerage houses, banks and other custodians, nominees or fiduciaries, and, upon request, will reimburse such organizations or individuals for their reasonable expenses in forwarding soliciting materials to beneficial owners and in obtaining authorization for the execution of proxies.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		71

Additional Information

 

Stockholder Proposals for Inclusion in Our 2025 Annual Meeting Proxy Statement and Proxy Card

 

Under Exchange Act Rule 14a-8 (“Rule 14a-8”), any stockholder proposal to be considered by us for inclusion in our 2025 proxy statement and form of proxy card for next year’s annual meeting of stockholders, expected to be held in May 2025, must be received by our corporate secretary at our principal executive offices located at 400 Crossing Boulevard, Bridgewater, New Jersey 08807, not later than November 22, 2024 and must otherwise comply with Rule 14a-8. While the Board will consider stockholder proposals that we receive, we reserve the right to omit from our proxy statement stockholder proposals that do not satisfy applicable SEC rules.

 

Director Nominations and Other Proposals to Be Presented at Our 2025 Annual Meeting

 

In addition, our Bylaws establish advance notice and other procedures with regard to stockholder nominations for director or any other stockholder proposals to be brought before an annual meeting of stockholders that will not be included in our proxy statement. In general, notice must be received by our corporate secretary not less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting of stockholders and must contain specified information concerning the matters to be brought before the meeting and concerning the stockholder making the proposal. If no annual meeting was held in the previous year or if the annual meeting is called for a date that is more than 30 calendar days earlier or more than 60 calendar days later than such anniversary date, notice must be received not later than close of business on the 90^th day prior, nor earlier than close of business on the 120^th day prior, to the date of such annual meeting or, if the first public disclosure of the date of such annual meeting is less than 100 calendar days prior to the date of such annual meeting, the 10^th calendar day following the day on which public disclosure of the date of such annual meeting is first made by the Company. Therefore, to be presented at next year’s annual meeting, director nominations and stockholder proposals that will not be included in our proxy statement must be received by our corporate secretary at the address above on or after close of business on January 2, 2025 but not later than close of business on February 1, 2025 and must contain the information specified in our Bylaws. A nomination or proposal also must comply with the additional procedures set forth in our Bylaws.

 

In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than March 3, 2025.

 

Householding

 

Some brokers, banks and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports or notices of Internet availability of proxy materials, as applicable. This means that only one copy of such items may have been sent to multiple stockholders in your household. We will promptly deliver, without charge, a separate copy of these documents to you if you so request by writing or calling as follows: Amneal Pharmaceuticals, Inc., Attention: Corporate Secretary, 400 Crossing Boulevard, Bridgewater, NJ 08807; telephone, (908) 947-3120. If you want to receive separate copies of the annual report and proxy statement or notice of Internet availability of proxy materials, as applicable, in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your broker, bank or other nominee record holder, or you may contact us at the above address and phone number.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		72

Appendix A Non-GAAP Financial Measures

 

Non-GAAP Financial Measures

 

This Proxy Statement includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted earnings per share and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. Management uses these non-GAAP historical measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The Compensation Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations and trends while viewing the information through the eyes of management.

 

The calculation of non-GAAP adjusted diluted earnings per share assumes the conversion of all outstanding shares of Class B common stock to shares of Class A common stock.

 

These non-GAAP measures are subject to limitations. The non-GAAP measures presented herein may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner.

 

Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to net income, diluted earnings per share or any other measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

 

This Proxy Statement also includes certain non-GAAP forward-looking information, such as net leverage. The Company cannot, however, provide a reconciliation between non-GAAP targets and the most directly comparable GAAP measures without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, pandemic-related expenses, gains or losses related to changes in our tax receivable agreement liability, acquisition and site closure expenses, restructuring and other charges, inventory-related charges, charges related to legal matters, gains and losses on the sale of assets, impairment charges, and foreign exchange gains or losses. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results.

 

A reconciliation of each non-GAAP measure to the most directly comparable GAAP measure is set forth below.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		73

Reconciliation of Net Loss to Adjusted Net Income and Calculation of Adjusted Diluted EPS

 

(unaudited, in thousands, except EPS)		Year Ended December 31, 2023				Year Ended December 31, 2022
Net loss		$	(48,722	)		$	(254,789	)
Adjusted to add (deduct):
Non-cash interest			7,017				7,715
GAAP provision for income taxes			8,452				6,662
Amortization			157,219				164,997
Stock-based compensation expense			26,822				31,847
Acquisition, site closure expenses, and idle facility expenses(1)			7,017				15,682
Restructuring and other charges			1,650				1,378
Loss on refinancing			40,805				291
Charges related to legal matters, including interest, net(2)			14,784				273,226
Asset impairment charges(3)			70,015				26,843
Regulatory approval milestone			-				5,000
Change in fair value of contingent consideration			(14,497	)			731
Insurance recoveries for property losses and associated expenses			-				(1,911	)
Increase in tax receivable agreement liability			3,124				631
System implementation expense(4)			5,363				2,818
Reorganization expenses(5)			5,927				393
Other			2,466				(2,235	)
Provision for income taxes(6)			(60,014	)			(56,450	)
Net income attributable to non-controlling interests not associated with our class B common stock			(29,873	)			(15,121	)
ADJUSTED NET INCOME (NON-GAAP)		$	197,555			$	207,708
Weighted average diluted shares outstanding (Non-GAAP)(7)			310,234				304,598
ADJUSTED DILUTED EARNINGS PER SHARE (NON-GAAP)		$	0.64			$	0.68

 

(1)	Acquisition, site closure, and idle facility expenses for the year ended December 31, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility. Acquisition, site closure, and idle facility expenses for the year ended December 31, 2022 primarily included (i) transaction and integration costs associated with the acquisition of the baclofen franchise from certain entities affiliated with Saol International Limited, which closed on February 9, 2022; (ii) integration costs associated with the acquisition of Puniska Healthcare Pvt. Ltd., which closed on November 2, 2021; and (iii) site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility.
(2)	For the year ended December 31, 2023, charges related to legal matters, net were primarily comprised of (i) charges associated with civil prescription opioid litigation, (ii) a settlement of a customer claim, (iii) a settlement of commercial antitrust litigation, and (iv) a settlement of a stockholder derivative lawsuit. For the year ended December 31, 2022, charges related to legal matters, net, primarily included charges for (i) the settlements of the Opana ER® antitrust litigation and (ii) prescription opioid litigation, offset in part by insurance recoveries associated with class action shareholder lawsuits.
(3)	Asset impairment charges for the year ended December 31, 2023 were primarily associated with the write-offs of intangible assets. Asset impairment charges for the year ended December 31, 2022 were associated with the write-offs of intangible assets and equipment.
(4)	System implementation expense for the years ended December 31, 2023 and 2022 was primarily for the implementation of indirect procurement software, sales deduction software, and financial statement consolidation software. System implementation expenses were associated with the further integration of our acquired businesses.
(5)	On November 7, 2023, the Company implemented a plan to reorganize and simplify its corporate structure by eliminating its umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure, whereby all stockholders hold their voting and economic interests directly through the public company (“Reorganization”). For the years ended December 31, 2023 and 2022, Reorganization expenses were comprised of professional fees.
(6)	The non-GAAP effective tax rates for the years ended December 31, 2023 and 2022 were 23.3% and 21.4%, respectively.
(7)	Weighted average diluted shares outstanding consisted of class A common stock and class B common stock, as if all shares of class B common stock were converted to class A common stock as of January 1, 2022.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		74

Reconciliation of Net Loss to EBITDA and Adjusted EBITDA

 

(unaudited, in thousands)		Year Ended December 31, 2023				Year Ended December 31, 2022				Year Ended December 31, 2019(1)
Net loss		$	(48,722	)		$	(254,789	)		$	(603,573	)
Adjusted to add:
Interest expense, net			210,629				158,377				168,205
Provision for income taxes			8,452				6,662				383,331
Depreciation and amortization			229,400				240,175				207,235
EBITDA (Non-GAAP)		$	399,759			$	150,425			$	155,198
Adjusted to add (deduct):
Stock-based compensation expense			26,822				31,847				21,679
Acquisition, site closure, and idle facility expenses(2)			7,017				15,682				73,471
Restructuring and other charges(3)			1,650				1,378				34,345
Loss on refinancing			40,805				291				-
Inventory related charges (4)			-				-				25,677
Charges related to legal matters, net(5)			11,824				269,930				12,591
Asset impairment charges(6)			70,107				26,909				175,210
Foreign exchange (gain) loss			(1,671	)			12,364				4,962
Change in fair value of contingent consideration			(14,497	)			731				-
Amortization of upfront payment(7)			-				-				36,393
Gain on sale of international businesses, net(8)			-				-				(7,258	)
Insurance recoveries for property losses and associated expenses			-				(1,911	)			-
Regulatory approval milestone			-				5,000				-
Increase (decrease) in tax receivable agreement liability(9)			3,124				631				(192,884	)
System implementation expense(10)			5,363				2,818				-
Reorganization expenses(11)			5,927				393				-
Other			1,984				(2,378	)			(446	)
ADJUSTED EBITDA (NON-GAAP)		$	558,214			$	514,110			$	338,938

 

(1)	Beginning in the first quarter of 2022, we no longer excluded research and development milestone expenses related to license and collaboration agreements from our non-GAAP financial measures and our line item components, including adjusted EBITDA. Adjusted results for the year ended December 31, 2019 have been revised to reflect this change.
(2)	Acquisition, site closure, and idle facility expenses for the year ended December 31, 2023 primarily included site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility. Acquisition, site closure, and idle facility expenses for the year ended December 31, 2022 primarily included (i) transaction and integration costs associated with the acquisition of the baclofen franchise from certain entities affiliated with Saol International Limited, which closed on February 9, 2022; (ii) integration costs associated with the acquisition of Puniska Healthcare Pvt. Ltd., which closed on November 2, 2021; and (iii) site closure costs associated with the planned cessation of manufacturing at our Hauppauge, NY facility. Acquisition, site closure, and idle facility expenses for the year ended December 31, 2019 primarily included costs related to (i) plant closure and redundant employee costs and (ii) third party costs associated with the combination with Impax Laboratories, Inc. ("Impax") and related integration including legal, investment banking, accounting and information technology.
(3)	For the year ended December 31, 2019, restructuring and other charges were primarily associated with cash severance provided pursuant to our severance programs for employees at our Hauppauge, NY, Hayward, CA and other facilities as well as asset-related charges associated with the impairment of property, plant and equipment and the right of use asset associated with our Hauppauge, NY facility.
(4)	For the year ended December 31, 2019, inventory related charges primarily represented inventory obsolescence resulting from new initiatives and policies adopted with our restructuring efforts.
(5)	For the year ended December 31, 2023, charges related to legal matters, net were primarily comprised of (i) charges associated with civil prescription opioid litigation, (ii) a settlement of a customer claim, (iii) a settlement of commercial antitrust litigation, and (iv) a settlement of a stockholder derivative lawsuit. For the year ended December 31, 2022, charges related to legal matters, net, primarily included charges for (i) the settlements of the Opana ER® antitrust litigation and (ii) prescription opioid litigation, offset in part by insurance recoveries associated with class action shareholder lawsuits. For the year ended December 31, 2019, charges related to legal matters, net were primarily associated with a settlement agreement with Teva Pharmaceuticals, Inc. regarding a matter associated with Impax prior to the business combination.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		75

(6)	Asset impairment charges for the year ended December 31, 2023 were primarily associated with the write-offs of intangible assets. Asset impairment charges for the year ended December 31, 2022 were associated with the write-offs of intangible assets and equipment. Asset impairment charges for the year ended December 31, 2019 were primarily associated with the write-off of in process research and development and intangible asset impairment charges primarily related to products acquired in the Impax business combination.
(7)	Amortization of upfront payment for the year ended December 31, 2019 represented the amortization of the upfront payment made to Lannett Company in connection with our transition agreement for Levothyroxine.
(8)	For the year ended December 31, 2019 gain on sale of international business, net represented the gain from the sale of our Creo Pharma Holding Limited subsidiary, which comprised substantially all of the Company's operations in the United Kingdom, partially offset by the loss from the sale of our Amneal Deutschland GmbH subsidiary, which comprised substantially all of the Company's operations in Germany.
(9)	During the year ended December 31, 2019, we recorded a valuation allowance to reduce our deferred tax assets (“DTAs”) to zero. In conjunction with the valuation allowance on our DTAs, we reversed the accrued TRA liability, which resulted in a $193 million gain to our statement of operations.
(10)	System implementation expense for the years ended December 31, 2023 and 2022 was primarily for the implementation of indirect procurement software, sales deduction software, and financial statement consolidation software. System implementation expenses were associated with the further integration of our acquired businesses.
(11)	On November 7, 2023, the Company implemented a plan to reorganize and simplify its corporate structure by eliminating its umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure, whereby all stockholders hold their voting and economic interests directly through the public company (“Reorganization”). For the years ended December 31, 2023 and 2022, Reorganization expenses were comprised of professional fees.

 

www.amneal.com		AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		76

Calculation of Gross Leverage and Net Leverage

 

		Year Ended December 31,
(unaudited, in thousands)		2023				2019
EBITDA		$	399,759			$	155,198
Adjusted EBITDA		$	558,214			$	338,938

 

(unaudited, in thousands)		As of December 31, 2023				As of December 31, 2019
Term Loan Due 2025(1)		$	191,979			$	2,658,876
Term Loan Due 2028(1)			2,351,647				—
Amended New Revolving Credit Facility(1)			179,000				—
Sellers Notes(1)			44,200				—
Other			—				624
Gross debt		$	2,766,826			$	2,659,500
Less: Cash and cash equivalents			(91,542	)			(151,197	)
NET DEBT		$	2,675,284			$	2,508,303

 

		Year Ended December 31,
(unaudited)		2023		2019
Gross leverage (Gross debt divided by Adjusted EBITDA)		5.0x		7.8x
Net leverage (Net debt divided by Adjusted EBITDA)		4.8x		7.4x

 

(1)	As defined in Note 16 in our 2023 Annual Report on Form 10-K.

 

	AMNEAL PHARMACEUTICALS, INC.  |  2024 Proxy Statement		77

v3.24.1

Cover	12 Months Ended
	Dec. 31, 2023
Cover [Abstract]
Document Type	DEF 14A
Entity Registrant Name	Amneal Pharmaceuticals, Inc.
Entity Central Index Key	0001723128
Amendment Flag	false

v3.24.1

Pay vs Performance Disclosure - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Pay vs Performance Disclosure [Table]
Pay vs Performance [Table Text Block]		Pay Versus Performance Disclosure   In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown. The sum and/or computation of individual numerical amounts disclosed in the following tables and related footnotes may not equal the total due to rounding.                               Value of Initial Fixed $100 Investment based on(4)       Year   Summary Compensation Table Total for Chirag Patel(1) ($)   Summary Compensation Table Total for Chintu Patel(1) ($)   Compensation Actually Paid to Chirag Patel(1)(2)(3) ($)   Compensation Actually Paid to Chintu Patel(1)(2)(3) ($)   Average Summary Compensation Table Total for Non-PEO NEOs(1) ($)   Average Compensation Actually Paid to Non-PEO NEOs(1)(2)(3) ($)   TSR ($)   Peer Group TSR ($)   Net Income (Loss) ($ Millions)   Adjusted EBITDA ($ Millions)(5) (a)   (b)   (b)   (c)   (c)   (d)   (e)   (f)   (g)   (h)   (i) 2023   2,370,386   2,367,553   9,458,710   9,455,877   1,679,146   5,801,457   125.93   124.97   (89)   558 2022   5,048,110   5,062,732   (1,835,706)   (1,821,083)   2,348,670   (121,995)   41.29   123.43   (255)   514 2021   4,785,116   4,798,825   1,383,918   1,397,627   2,420,041   1,421,310   99.38   129.31   20   538 2020   2,320,716   2,328,528   3,422,575   3,430,387   1,922,858   1,985,608   94.81   114.32   69   433 (1) Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.   2020 2021 2022 2023 Andrew Boyer Andrew Boyer Andrew Boyer Andrew Boyer Anastasios Konidaris Anastasios Konidaris Anastasios Konidaris Anastasios Konidaris Nikita Shah Nikita Shah Nikita Shah Nikita Shah Joseph Todisco Joseph Todisco Jason Daly Jason Daly Todd Branning         (2) The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below. (3) Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the amounts from the Stock Awards column set forth in the Summary Compensation Table. (4) The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019 (the last trading day of fiscal 2019), through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. (5) We determined adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. We may determine a different financial performance measure to be the most important financial performance measure in future years. Adjusted EBITDA is not a term defined under U.S. GAAP. We define adjusted EBITDA as net income before net interest expense, income taxes, and depreciation and amortization (“EBITDA”), as adjusted for certain other items described in our SEC filings, including stock-based compensation expense, acquisition, site closure and idle facility expenses, restructuring and other charges, net charges related to legal matters, asset impairment charges, foreign exchange losses or gains, change in fair value of contingent consideration, and insurance recoveries for property losses and associated expenses. Prior to January 1, 2022, research and development milestone expenses related to license and collaboration agreements were excluded from our calculation of adjusted EBITDA. The amounts shown in this column for the fiscal years ended December 31, 2021 and December 31, 2020 reflect this historical approach. Effective January 1, 2022, we no longer exclude research and development milestone expenses related to license and collaboration agreements from adjusted EBITDA. The amounts shown in this column for the fiscal year ended December 31, 2023 and December 31, 2022 reflect this modified approach; for prior periods, refer to our Form 8-K filed with the Securities and Exchange Commission on May 4, 2022 for a full reconciliation of previously reported non-GAAP results, including adjusted EBITDA, to revised non-GAAP results. As a result of this modified approach, our reported adjusted EBITDA for the fiscal years ended December 31, 2021 and December 31, 2020 was revised to $512 million and $433 million, respectively.   (1) Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.   2020 2021 2022 2023 Andrew Boyer Andrew Boyer Andrew Boyer Andrew Boyer Anastasios Konidaris Anastasios Konidaris Anastasios Konidaris Anastasios Konidaris Nikita Shah Nikita Shah Nikita Shah Nikita Shah Joseph Todisco Joseph Todisco Jason Daly Jason Daly Todd Branning       (2) The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below. (3) Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the amounts from the Stock Awards column set forth in the Summary Compensation Table.   Year   Summary Compensation Table Total for Chirag Patel ($)   Exclusion of Stock Awards for Chirag Patel ($)   Inclusion of Equity Values for Chirag Patel ($)   Compensation Actually Paid to Chirag Patel ($) 2023   2,370,386   (664,219)   7,752,544   9,458,710                   Year   Summary Compensation Table Total for Chintu Patel ($)   Exclusion of Stock Awards for Chintu Patel ($)   Inclusion of Equity Values for Chintu Patel ($)   Compensation Actually Paid to Chintu Patel ($) 2023   2,367,553   (664,219)   7,752,544   9,455,877   Year   Average Summary Compensation Table Total for Non-PEO NEOs ($)   Average Exclusion of Stock Awards and Option Awards for Non- PEO NEOs ($)   Average Inclusion of Equity Values for Non- PEO NEOs ($)   Average Compensation Actually Paid to Non- PEO NEOs ($) 2023   1,679,146   (712,920)   4,835,231   5,801,457   The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:   Year   Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Chirag Patel ($)   Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Chirag Patel ($)   Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Chirag Patel ($)   Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Chirag Patel ($)   Total - Inclusion of Equity Values for Chirag Patel ($) 2023   3,526,601   4,225,943   —   —   7,752,544                       Year   Year-End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Chintu Patel ($)   Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Chintu Patel ($)   Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Chintu Patel ($)   Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Chintu Patel ($)   Total - Inclusion of Equity Values for Chintu Patel ($) 2023   3,526,601   4,225,943   —   —   7,752,544                         Year   Average Year- End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Non- PEO NEOs ($)   Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($)   Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non- PEO NEOs ($)   Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non- PEO NEOs ($)   Total - Average Inclusion of Equity Values for Non-PEO NEOs ($) 2023   2,996,942   1,838,427   (137)   —   4,835,231   (4) The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019 (the last trading day of fiscal 2019), through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. (5) We determined adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. We may determine a different financial performance measure to be the most important financial performance measure in future years. Adjusted EBITDA is not a term defined under U.S. GAAP. We define adjusted EBITDA as net income before net interest expense, income taxes, and depreciation and amortization (“EBITDA”), as adjusted for certain other items described in our SEC filings, including stock-based compensation expense, acquisition, site closure and idle facility expenses, restructuring and other charges, net charges related to legal matters, asset impairment charges, foreign exchange losses or gains, change in fair value of contingent consideration, and insurance recoveries for property losses and associated expenses. Prior to January 1, 2022, research and development milestone expenses related to license and collaboration agreements were excluded from our calculation of adjusted EBITDA. The amounts shown in this column for the fiscal years ended December 31, 2021 and December 31, 2020 reflect this historical approach. Effective January 1, 2022, we no longer exclude research and development milestone expenses related to license and collaboration agreements from adjusted EBITDA. The amounts shown in this column for the fiscal year ended December 31, 2023 and December 31, 2022 reflect this modified approach; for prior periods, refer to our Form 8-K filed with the Securities and Exchange Commission on May 4, 2022 for a full reconciliation of previously reported non-GAAP results, including adjusted EBITDA, to revised non-GAAP results. As a result of this modified approach, our reported adjusted EBITDA for the fiscal years ended December 31, 2021 and December 31, 2020 was revised to $512 million and $433 million, respectively.
Company Selected Measure Name		adjusted EBITDA
Named Executive Officers, Footnote [Text Block]		(1) Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.   2020 2021 2022 2023 Andrew Boyer Andrew Boyer Andrew Boyer Andrew Boyer Anastasios Konidaris Anastasios Konidaris Anastasios Konidaris Anastasios Konidaris Nikita Shah Nikita Shah Nikita Shah Nikita Shah Joseph Todisco Joseph Todisco Jason Daly Jason Daly Todd Branning
Peer Group Issuers, Footnote [Text Block]		The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019 (the last trading day of fiscal 2019), through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
Adjustment To PEO Compensation, Footnote [Text Block]		Year   Summary Compensation Table Total for Chirag Patel ($)   Exclusion of Stock Awards for Chirag Patel ($)   Inclusion of Equity Values for Chirag Patel ($)   Compensation Actually Paid to Chirag Patel ($) 2023   2,370,386   (664,219)   7,752,544   9,458,710                   Year   Summary Compensation Table Total for Chintu Patel ($)   Exclusion of Stock Awards for Chintu Patel ($)   Inclusion of Equity Values for Chintu Patel ($)   Compensation Actually Paid to Chintu Patel ($) 2023   2,367,553   (664,219)   7,752,544   9,455,877   Year   Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Chirag Patel ($)   Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Chirag Patel ($)   Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Chirag Patel ($)   Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Chirag Patel ($)   Total - Inclusion of Equity Values for Chirag Patel ($) 2023   3,526,601   4,225,943   —   —   7,752,544                       Year   Year-End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Chintu Patel ($)   Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Chintu Patel ($)   Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Chintu Patel ($)   Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Chintu Patel ($)   Total - Inclusion of Equity Values for Chintu Patel ($) 2023   3,526,601   4,225,943   —   —   7,752,544
Non-PEO NEO Average Total Compensation Amount	[1]	$ 1,679,146	$ 2,348,670	$ 2,420,041	$ 1,922,858
Non-PEO NEO Average Compensation Actually Paid Amount	[1],[2],[3]	$ 5,801,457	(121,995)	1,421,310	1,985,608
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]		Year   Average Summary Compensation Table Total for Non-PEO NEOs ($)   Average Exclusion of Stock Awards and Option Awards for Non- PEO NEOs ($)   Average Inclusion of Equity Values for Non- PEO NEOs ($)   Average Compensation Actually Paid to Non- PEO NEOs ($) 2023   1,679,146   (712,920)   4,835,231   5,801,457                         Year   Average Year- End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year for Non- PEO NEOs ($)   Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($)   Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non- PEO NEOs ($)   Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non- PEO NEOs ($)   Total - Average Inclusion of Equity Values for Non-PEO NEOs ($) 2023   2,996,942   1,838,427   (137)   —   4,835,231
Compensation Actually Paid vs. Total Shareholder Return [Text Block]		The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the four most recently completed fiscal years.
Compensation Actually Paid vs. Net Income [Text Block]		The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and our net income during the four most recently completed fiscal years.
Compensation Actually Paid vs. Company Selected Measure [Text Block]		The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Adjusted EBITDA during the four most recently completed fiscal years.
Total Shareholder Return Vs Peer Group [Text Block]		The following chart sets forth the relationship between Compensation Actually Paid to our PEOs, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative TSR over the four most recently completed fiscal years.
Tabular List [Table Text Block]		Tabular List of Most Important Financial Performance Measures   The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEOs and other NEOs for 2023 to Company performance. The measures in this table are not ranked.   Adjusted EBITDA Stock Price   #        #        #
Total Shareholder Return Amount	[4]	$ 125.93	41.29	99.38	94.81
Peer Group Total Shareholder Return Amount	[4]	124.97	123.43	129.31	114.32
Net Income (Loss) Attributable to Parent		$ (89,000,000)	$ (255,000,000)	$ 20,000,000	$ 69,000,000
Company Selected Measure Amount	[5]	558,000,000	514,000,000	538,000,000	433,000,000
Measure [Axis]: 1
Pay vs Performance Disclosure [Table]
Measure Name		Adjusted EBITDA
Measure [Axis]: 2
Pay vs Performance Disclosure [Table]
Measure Name		Stock Price
Non-PEO NEO [Member] | Average Exclusion of Stock Awards and Option Awards
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		$ (712,920)
Non-PEO NEO [Member] | Average Inclusion of Equity Values
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		4,835,231
Non-PEO NEO [Member] | Average Year- End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		2,996,942
Non-PEO NEO [Member] | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		1,838,427
Non-PEO NEO [Member] | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		(137)
Non-PEO NEO [Member] | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount
Chirag Patel
Pay vs Performance Disclosure [Table]
PEO Total Compensation Amount	[1]	2,370,386	$ 5,048,110	$ 4,785,116	$ 2,320,716
PEO Actually Paid Compensation Amount	[1],[2],[3]	$ 9,458,710	$ (1,835,706)	$ 1,383,918	$ 3,422,575
PEO Name		Chirag Patel	Chirag Patel	Chirag Patel	Chirag Patel
Chirag Patel | PEO [Member] | Exclusion of Stock Awards
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		$ (664,219)
Chirag Patel | PEO [Member] | Inclusion of Equity Values
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		7,752,544
Chirag Patel | PEO [Member] | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		3,526,601
Chirag Patel | PEO [Member] | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		4,225,943
Chirag Patel | PEO [Member] | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount
Chirag Patel | PEO [Member] | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount
Chintu Patel
Pay vs Performance Disclosure [Table]
PEO Total Compensation Amount	[1]	2,367,553	$ 5,062,732	$ 4,798,825	$ 2,328,528
PEO Actually Paid Compensation Amount	[1],[2],[3]	$ 9,455,877	$ (1,821,083)	$ 1,397,627	$ 3,430,387
PEO Name		Chintu Patel	Chintu Patel	Chintu Patel	Chintu Patel
Chintu Patel | PEO [Member] | Exclusion of Stock Awards
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		$ (664,219)
Chintu Patel | PEO [Member] | Inclusion of Equity Values
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		7,752,544
Chintu Patel | PEO [Member] | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		4,225,943
Chintu Patel | PEO [Member] | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount
Chintu Patel | PEO [Member] | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount
Chintu Patel | PEO [Member] | Year-End Fair Value of Equity Awards Granted During Year That Remained Outstanding and Unvested as of Last Day of Year
Pay vs Performance Disclosure [Table]
Adjustment to Compensation Amount		$ 3,526,601
[1] Chirag Patel and Chintu Patel were our Co-PEOs for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below. [2] Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEOs and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the amounts from the Stock Awards column set forth in the Summary Compensation Table. [3] The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below. [4] The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K, included in our Annual Report for the year ended December 31, 2023. The comparison assumes $100 was invested for the period starting December 31, 2019 (the last trading day of fiscal 2019), through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. [5] We determined adjusted EBITDA to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEOs and Non-PEO NEOs in 2023. We may determine a different financial performance measure to be the most important financial performance measure in future years. Adjusted EBITDA is not a term defined under U.S. GAAP. We define adjusted EBITDA as net income before net interest expense, income taxes, and depreciation and amortization (“EBITDA”), as adjusted for certain other items described in our SEC filings, including stock-based compensation expense, acquisition, site closure and idle facility expenses, restructuring and other charges, net charges related to legal matters, asset impairment charges, foreign exchange losses or gains, change in fair value of contingent consideration, and insurance recoveries for property losses and associated expenses. Prior to January 1, 2022, research and development milestone expenses related to license and collaboration agreements were excluded from our calculation of adjusted EBITDA. The amounts shown in this column for the fiscal years ended December 31, 2021 and December 31, 2020 reflect this historical approach. Effective January 1, 2022, we no longer exclude research and development milestone expenses related to license and collaboration agreements from adjusted EBITDA. The amounts shown in this column for the fiscal year ended December 31, 2023 and December 31, 2022 reflect this modified approach; for prior periods, refer to our Form 8-K filed with the Securities and Exchange Commission on May 4, 2022 for a full reconciliation of previously reported non-GAAP results, including adjusted EBITDA, to revised non-GAAP results. As a result of this modified approach, our reported adjusted EBITDA for the fiscal years ended December 31, 2021 and December 31, 2020 was revised to $512 million and $433 million, respectively.

---